phthalazines - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	phthalazines	go back to main search page
Accession:	CHEBI:38768	browse the term

show annotations for term's descendants Sort by:
Rat (822) Mouse (828) Human (866) Chinchilla (0) Bonobo (0) Dog (0) Squirrel (0) Pig (0) Green Monkey (0) Naked Mole-rat (0) All
Genes (822)

(4-oxo-3-\{[5-(trifluoromethyl)-1,3-benzothiazol-2-yl]methyl\}-3,4-dihydrophthalazin-1-yl)acetic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aldo-keto reductase family 1 member B1

decreases activity
multiple interactions

zopolrestat results in decreased activity of AKR1B1 protein
[zopolrestat results in decreased activity of AKR1B1 protein] inhibits the reaction [Antigens, Plant results in increased abundance of Reactive Oxygen Species]; [zopolrestat results in decreased activity of AKR1B1 protein] inhibits the reaction [Antigens, Plant results in increased secretion of Dinoprostone]; [zopolrestat results in decreased activity of AKR1B1 protein] which results in decreased susceptibility to Antigens, Plant

NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157

G

aldo-keto reductase family 1 member B10

multiple interactions
decreases activity

zopolrestat inhibits the reaction [AKR1B10 protein results in increased reduction of Daunorubicin]; zopolrestat inhibits the reaction [AKR1B10 protein results in increased reduction of Glyceraldehyde]
zopolrestat results in decreased activity of AKR1B10 protein; zopolrestat results in decreased activity of AKR1B10 protein mutant form

PMID:18325492 PMID:19028477

NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852

G

C-C motif chemokine ligand 4

multiple interactions

zopolrestat inhibits the reaction [Antigens, Plant results in increased expression of CCL4 mRNA]

NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231

G

C-C motif chemokine ligand 5

multiple interactions

zopolrestat inhibits the reaction [Antigens, Plant results in increased expression of CCL5 mRNA]

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

interleukin 10

multiple interactions

zopolrestat inhibits the reaction [Antigens, Plant results in increased expression of IL10 mRNA]

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 13

multiple interactions

zopolrestat inhibits the reaction [Antigens, Plant results in increased expression of IL13 mRNA]

NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737

G

interleukin 18

multiple interactions

zopolrestat inhibits the reaction [Antigens, Plant results in increased expression of IL18 mRNA]

NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887

G

interleukin 4

multiple interactions

zopolrestat inhibits the reaction [Antigens, Plant results in increased expression of IL4 mRNA]

NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750

G

interleukin 5

multiple interactions

zopolrestat inhibits the reaction [Antigens, Plant results in increased expression of IL5 mRNA]

NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213

G

interleukin 6

multiple interactions

zopolrestat inhibits the reaction [Antigens, Plant results in increased expression of IL6 mRNA]
zopolrestat inhibits the reaction [Antigens, Plant results in increased secretion of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

Janus kinase 2

multiple interactions

zopolrestat results in decreased phosphorylation of and results in decreased activity of JAK2 protein

NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189

G

nitric oxide synthase 2

multiple interactions

zopolrestat inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 mRNA]; zopolrestat inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of NOS2 protein]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

prostaglandin-endoperoxide synthase 2

multiple interactions

zopolrestat inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of PTGS2 mRNA]; zopolrestat inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of PTGS2 protein]

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

zopolrestat inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of RELA protein]; zopolrestat inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

signal transducer and activator of transcription 5A

multiple interactions

zopolrestat results in decreased phosphorylation of and results in decreased activity of STAT5A protein

NCBI chr10:85,785,537...85,809,869
Ensembl chr10:85,785,537...85,809,866

G

tumor necrosis factor

multiple interactions

zopolrestat inhibits the reaction [Antigens, Plant results in increased expression of TNF mRNA]; zopolrestat inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]

PMID:21334316 PMID:24021941

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

azelastine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

multiple interactions
decreases activity

azelastine inhibits the reaction [ABCB1 protein results in increased transport of Daunorubicin]; azelastine inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]
azelastine results in decreased activity of ABCB1 protein

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

acetylcholinesterase

decreases activity

azelastine results in decreased activity of ACHE protein

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

collagen type I alpha 1 chain

decreases expression

azelastine results in decreased expression of COL1A1 mRNA

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

collagen type III alpha 1 chain

decreases expression

azelastine results in decreased expression of COL3A1 mRNA

NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547

G

collagen type VI alpha 1 chain

decreases expression

azelastine results in decreased expression of COL6A1 mRNA

NCBI chr20:11,906,105...11,924,599
Ensembl chr20:11,905,957...11,924,597

G

histamine receptor H 1

affects binding

azelastine binds to HRH1 protein

NCBI chr 4:147,564,963...147,649,353
Ensembl chr 4:147,645,995...147,647,455

G

potassium voltage-gated channel subfamily H member 2

decreases activity

azelastine results in decreased activity of KCNH2 protein

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

solute carrier family 22 member 2

multiple interactions

azelastine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268

Desmethylazelastine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

decreases activity
multiple interactions

desmethylazelastine results in decreased activity of ABCB1 protein
desmethylazelastine inhibits the reaction [ABCB1 protein results in increased transport of Daunorubicin]; desmethylazelastine inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

dihydralazine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

renin

increases activity

Dihydralazine results in increased activity of REN protein

NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489

hydralazine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 5

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in decreased expression of ABCB5 mRNA

NCBI chr 6:139,836,528...139,932,830
Ensembl chr 6:139,835,949...139,932,830

G

acetyl-CoA acyltransferase 1A

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ACAA1 mRNA

NCBI chr 8:119,079,401...119,088,626
Ensembl chr 8:119,079,775...119,088,624

G

acyl-CoA dehydrogenase family, member 9

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ACAD9 mRNA

NCBI chr 2:118,943,170...118,966,150
Ensembl chr 2:118,943,174...118,966,547

G

acetyl-CoA acetyltransferase 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ACAT2 mRNA

NCBI chr 1:47,695,833...47,713,879
Ensembl chr 1:47,695,788...47,752,821

G

angiotensin I converting enzyme

multiple interactions

Hydralazine inhibits the reaction [Nitric Oxide deficiency results in increased expression of ACE mRNA]

NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131

G

apoptotic chromatin condensation inducer 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ACIN1 mRNA

NCBI chr15:28,102,112...28,147,001
Ensembl chr15:28,102,112...28,147,001

G

acyl-CoA thioesterase 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in decreased expression of ACOT2 mRNA

NCBI chr 6:103,611,738...103,619,404
Ensembl chr 6:103,611,544...103,619,245

G

actin, alpha 1, skeletal muscle

multiple interactions

Hydralazine inhibits the reaction [Nitric Oxide deficiency results in increased expression of ACTA1 mRNA]

NCBI chr19:51,883,709...51,886,735
Ensembl chr19:51,883,715...51,886,742

G

ADAM metallopeptidase with thrombospondin type 1 motif, 10

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ADAMTS10 mRNA

NCBI chr 7:14,331,659...14,361,620
Ensembl chr 7:14,331,745...14,361,620

G

adhesion G protein-coupled receptor A3

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ADGRA3 mRNA

NCBI chr14:60,874,719...60,976,341
Ensembl chr14:60,874,715...60,976,332

G

adiponectin receptor 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ADIPOR1 mRNA

NCBI chr13:45,859,461...45,879,248
Ensembl chr13:45,859,533...45,879,241

G

adenylosuccinate lyase

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ADSL mRNA

NCBI chr 7:112,479,256...112,503,439
Ensembl chr 7:112,479,271...112,503,760

G

AFG3 like matrix AAA peptidase subunit 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of AFG3L2 mRNA

NCBI chr18:60,954,268...60,999,110
Ensembl chr18:60,954,268...60,999,110

G

acylglycerol kinase

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of AGK mRNA

NCBI chr 4:69,114,850...69,193,989
Ensembl chr 4:69,114,269...69,193,934

G

1-acylglycerol-3-phosphate O-acyltransferase 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in decreased expression of AGPAT2 mRNA

NCBI chr 3:9,416,837...9,428,567
Ensembl chr 3:9,416,843...9,428,371

G

angiotensinogen

multiple interactions
decreases response to substance

Hydralazine affects the reaction [AGT protein results in increased abundance of Fatty Acids, Nonesterified]; Hydralazine affects the reaction [AGT protein results in increased abundance of Triglycerides]; Hydralazine inhibits the reaction [AGT protein affects the abundance of Cholesterol]; Hydralazine inhibits the reaction [AGT protein modified form results in increased phosphorylation of MAPK1 protein]; Hydralazine inhibits the reaction [AGT protein modified form results in increased phosphorylation of MAPK3 protein]; Hydralazine inhibits the reaction [AGT protein results in decreased expression of CPT1A mRNA]
Hydralazine results in decreased susceptibility to AGT protein modified form

PMID:16344371 PMID:19109942 PMID:21289285

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

aldo-keto reductase family 1 member A1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of AKR1A1 mRNA

NCBI chr 5:130,092,945...130,130,277
Ensembl chr 5:130,092,732...130,113,674

G

aldo-keto reductase family 1, member C2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of AKR1C2 mRNA

NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764

G

AKT serine/threonine kinase 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of AKT2 mRNA

NCBI chr 1:82,877,228...82,933,828
Ensembl chr 1:82,883,547...82,933,817

G

albumin

multiple interactions
affects binding

Hydralazine inhibits the reaction [[Acrolein binds to ALB protein] which results in increased expression of HMOX1 mRNA]
Hydralazine binds to [Acrolein binds to ALB protein]

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

aldehyde dehydrogenase 18 family, member A1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ALDH18A1 mRNA

NCBI chr 1:239,375,657...239,407,956
Ensembl chr 1:239,375,669...239,407,890

G

aldehyde dehydrogenase 9 family, member A1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ALDH9A1 mRNA

NCBI chr13:79,505,738...79,522,539
Ensembl chr13:79,505,695...79,540,568

G

arachidonate 15-lipoxygenase

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in decreased expression of ALOX15 mRNA

NCBI chr10:55,060,169...55,068,885
Ensembl chr10:55,060,412...55,068,874

G

anaphase promoting complex subunit 11

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ANAPC11 mRNA

NCBI chr10:105,875,209...105,886,307

G

androgen regulated protein

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CST4 mRNA

NCBI chr 3:136,718,601...136,725,131
Ensembl chr 3:136,718,602...136,724,966

G

ankyrin-repeat and fibronectin type III domain containing 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ANKFN1 mRNA

NCBI chr10:74,214,143...74,602,825
Ensembl chr10:74,218,915...74,663,295

G

ankyrin repeat and KH domain containing 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ANKHD1 mRNA

NCBI chr18:28,161,882...28,260,917
Ensembl chr18:28,162,311...28,268,024

G

ankyrin repeat and IBR domain containing 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ANKIB1 mRNA

NCBI chr 4:30,333,678...30,457,781
Ensembl chr 4:30,333,677...30,457,781

G

ankyrin repeat domain 44

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ANKRD44 mRNA

NCBI chr 9:56,126,746...56,427,661
Ensembl chr 9:56,126,747...56,427,508

G

annexin A2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ANXA2 mRNA

NCBI chr 8:70,105,268...70,141,663
Ensembl chr 8:70,105,253...70,141,658

G

acyloxyacyl hydrolase

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in decreased expression of AOAH mRNA

NCBI chr17:43,808,110...44,049,458
Ensembl chr17:43,809,638...44,049,148

G

amine oxidase, copper containing 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of AOC1 mRNA

NCBI chr 4:77,812,260...77,831,846
Ensembl chr 4:77,812,260...77,831,840

G

APC regulator of WNT signaling pathway

decreases methylation

Hydralazine results in decreased methylation of APC promoter

NCBI chr18:25,828,558...25,925,511
Ensembl chr18:25,864,222...25,922,696

G

APC down-regulated 1 like

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of APCDD1L mRNA

NCBI chr 3:162,587,484...162,658,362
Ensembl chr 3:162,582,252...162,658,073

G

aquaporin 10

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of AQP10 mRNA

NCBI chr 2:175,402,609...175,407,677
Ensembl chr 2:175,403,263...175,406,815

G

archain 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ARCN1 mRNA

NCBI chr 8:45,057,617...45,082,224
Ensembl chr 8:45,057,619...45,082,247

G

ARF GTPase 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ARF1 mRNA

NCBI chr10:43,997,983...44,014,461
Ensembl chr10:43,997,986...44,014,434

G

Rho GTPase activating protein 23

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ARHGAP23 mRNA

NCBI chr10:82,437,578...82,496,846
Ensembl chr10:82,394,648...82,496,504

G

Rho GTPase activating protein 40

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ARHGAP40 mRNA

NCBI chr 3:147,165,781...147,206,552
Ensembl chr 3:147,165,729...147,207,203

G

Rho GTPase activating protein 5

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ARHGAP5 mRNA

NCBI chr 6:69,975,904...70,039,299
Ensembl chr 6:69,976,214...70,037,660

G

Rho guanine nucleotide exchange factor 12

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ARHGEF12 mRNA

NCBI chr 8:43,350,070...43,475,404
Ensembl chr 8:43,353,799...43,476,366

G

ariadne RBR E3 ubiquitin protein ligase 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ARIH2 mRNA

NCBI chr 8:109,296,738...109,355,909
Ensembl chr 8:109,296,738...109,355,852

G

ARF like GTPase 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ARL2 mRNA

NCBI chr 1:203,434,129...203,446,156
Ensembl chr 1:203,434,129...203,446,119

G

ARF like GTPase 6 interacting protein 5

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ARL6IP5 mRNA

NCBI chr 4:129,810,650...129,838,628
Ensembl chr 4:129,810,645...129,838,608

G

ADP-ribosyltransferase 4

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ART4 mRNA

NCBI chr 4:169,740,331...169,751,571
Ensembl chr 4:169,740,331...169,750,665

G

ArfGAP with SH3 domain, ankyrin repeat and PH domain 3

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of DDEFL1 mRNA

NCBI chr 5:148,433,382...148,476,027
Ensembl chr 5:148,433,494...148,474,073

G

ankyrin repeat and SOCS box-containing 7

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ASB7 mRNA

NCBI chr 1:120,222,835...120,267,411
Ensembl chr 1:120,222,745...120,267,282

G

acid sensing ion channel subunit family member 4

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ASIC4 mRNA

NCBI chr 9:76,941,532...76,962,900
Ensembl chr 9:76,941,532...76,962,900

G

aspartate-beta-hydroxylase

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ASPH mRNA

NCBI chr 5:22,601,581...22,814,107
Ensembl chr 5:22,603,486...22,813,876

G

activating transcription factor 3

multiple interactions

Hydralazine inhibits the reaction [Ethanol results in increased expression of ATF3 mRNA]

NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631

G

activating transcription factor 4

multiple interactions

Hydralazine inhibits the reaction [Ethanol results in increased expression of ATF4 mRNA]

NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446

G

autophagy related 10

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ATG10 mRNA

NCBI chr 2:22,109,304...22,398,313
Ensembl chr 2:22,108,426...22,398,233

G

ATPase 13A4

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ATP13A4 mRNA

NCBI chr11:71,222,196...71,359,933
Ensembl chr11:71,226,161...71,359,933

G

ATP synthase F1 subunit epsilon

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ATP5F1E mRNA

NCBI chr 3:163,259,072...163,261,974
Ensembl chr 3:163,260,476...163,261,450

G

ATP synthase membrane subunit c locus 3

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ATP5MC3 mRNA

NCBI chr 3:58,810,535...58,813,185
Ensembl chr 3:58,810,535...58,814,279

G

ATP synthase membrane subunit e

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ATP5ME mRNA

NCBI chr14:1,319,868...1,320,996
Ensembl chr14:1,319,868...1,321,013

G

ATP synthase peripheral stalk subunit F6

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ATP5PF mRNA

NCBI chr11:23,881,594...23,889,581
Ensembl chr11:23,881,592...23,889,119

G

ATPase H+ transporting accessory protein 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ATP6AP1 mRNA

NCBI chr X:152,079,954...152,087,034
Ensembl chr X:152,079,865...152,087,034

G

ATPase H+ transporting V1 subunit B1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ATP6V1B1 mRNA

NCBI chr 4:116,223,799...116,242,475
Ensembl chr 4:116,223,799...116,242,475

G

ATPase H+ transporting V1 subunit C1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ATP6V1C1 mRNA

NCBI chr 7:69,834,464...69,872,278
Ensembl chr 7:69,834,463...69,872,278

G

ataxin 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ATXN2 mRNA

NCBI chr12:34,754,132...34,851,175
Ensembl chr12:34,754,137...34,851,479

G

ataxin 7-like 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ATXN7L1 mRNA

NCBI chr 6:49,759,876...49,982,323
Ensembl chr 6:49,759,883...49,982,320

G

B9 domain containing 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in decreased expression of B9D1 mRNA

NCBI chr10:46,186,222...46,196,309
Ensembl chr10:46,186,691...46,196,008

G

BCL2-associated agonist of cell death

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of BAD mRNA

NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823

G

BAG cochaperone 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of BAG1 mRNA

NCBI chr 5:56,068,494...56,081,075
Ensembl chr 5:56,068,494...56,081,075

G

branched chain ketoacid dehydrogenase kinase

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of BCKDK mRNA

NCBI chr 1:182,515,335...182,520,007
Ensembl chr 1:182,515,327...182,536,633

G

bolA family member 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of BOLA1 mRNA

NCBI chr 2:183,758,515...183,771,445
Ensembl chr 2:183,758,441...183,781,576

G

bisphosphoglycerate mutase

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of BPGM mRNA

NCBI chr 4:63,139,730...63,168,581
Ensembl chr 4:63,140,018...63,168,581

G

BPI fold containing family B, member 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of BPIFB2 mRNA

NCBI chr 3:142,356,990...142,377,053
Ensembl chr 3:142,358,051...142,377,044

G

bromodomain PHD finger transcription factor

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of BPTF mRNA

NCBI chr10:91,980,279...92,082,731
Ensembl chr10:91,982,758...92,082,769

G

bromodomain containing 8

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of BRD8 mRNA

NCBI chr18:26,204,892...26,229,999
Ensembl chr18:26,181,732...26,229,884

G

C1q and TNF related 5

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of C1QTNF5 mRNA

NCBI chr 8:44,450,934...44,453,075
Ensembl chr 8:44,451,154...44,453,074

G

complement C4A

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of C4A mRNA

NCBI chr20:4,005,731...4,020,083
Ensembl chr20:4,005,731...4,020,080

G

similar to human chromosome 9 open reading frame 152

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of C9ORF152 mRNA

NCBI chr 5:72,660,573...72,667,941
Ensembl chr 5:72,660,573...72,668,379

G

similar to human chromosome 3 open reading frame 62

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of C3ORF62 mRNA

NCBI chr 8:109,080,032...109,084,588
Ensembl chr 8:109,036,030...109,097,895

G

similar to human chromosome 6 open reading frame 132

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of C6ORF132 mRNA

NCBI chr 9:13,524,822...13,561,756
Ensembl chr 9:13,525,395...13,561,585

G

calcium voltage-gated channel auxiliary subunit gamma 6

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CACNG6 mRNA

NCBI chr 1:65,732,910...65,747,377
Ensembl chr 1:65,732,632...65,747,341

G

calcium modulating ligand

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CAMLG mRNA

NCBI chr17:8,992,697...9,003,576
Ensembl chr17:8,992,696...9,003,552

G

calnexin

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CANX mRNA

NCBI chr10:34,623,865...34,656,866
Ensembl chr10:34,625,191...34,656,821

G

carbonic anhydrase 7

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CA7 mRNA

NCBI chr19:429,063...438,478
Ensembl chr19:429,075...438,467

G

carbonic anhydrase 8

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in decreased expression of CA8 mRNA

NCBI chr 5:21,302,940...21,402,395
Ensembl chr 5:21,305,383...21,402,374

G

CAS1 domain containing 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CASD1 mRNA

NCBI chr 4:32,659,196...32,739,228
Ensembl chr 4:32,658,748...32,739,202

G

caspase 12

multiple interactions

Hydralazine inhibits the reaction [Ethanol results in increased cleavage of CASP12 protein]

NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037

G

chromobox 7

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CBX7 mRNA

NCBI chr 7:111,460,656...111,479,231
Ensembl chr 7:111,460,656...111,477,973

G

coiled-coil domain containing 138

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CCDC138 mRNA

NCBI chr20:26,493,624...26,572,367
Ensembl chr20:26,495,235...26,572,376

G

coiled-coil domain containing 146

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in decreased expression of CCDC146 mRNA

NCBI chr 4:13,662,766...13,811,619
Ensembl chr 4:13,662,766...13,811,608

G

coiled-coil domain containing 47

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CCDC47 mRNA

NCBI chr10:91,130,303...91,148,829
Ensembl chr10:91,130,303...91,148,881

G

coiled-coil domain containing 82

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CCDC82 mRNA

NCBI chr 8:10,227,727...10,265,963
Ensembl chr 8:10,228,430...10,265,963

G

C-C motif chemokine ligand 22

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CCL22 mRNA

NCBI chr19:10,257,602...10,264,373
Ensembl chr19:10,257,601...10,264,400

G

C-C motif chemokine ligand 28

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CCL28 mRNA

NCBI chr 2:51,601,354...51,625,999
Ensembl chr 2:51,601,331...51,625,997

G

C-C motif chemokine ligand 4

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CCL4 mRNA

NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231

G

CCM2 scaffold protein

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CCM2 mRNA

NCBI chr14:81,418,418...81,464,114
Ensembl chr14:81,418,236...81,464,116

G

chaperonin containing TCP1 subunit 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CCT2 mRNA

NCBI chr 7:52,692,725...52,705,478
Ensembl chr 7:52,692,725...52,706,944

G

chaperonin containing TCP1 subunit 7

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CCT7 mRNA

NCBI chr 4:117,989,232...118,006,478
Ensembl chr 4:117,989,232...118,006,580

G

Cd63 molecule

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CD63 mRNA

NCBI chr 7:1,325,108...1,340,447
Ensembl chr 7:1,325,103...1,399,178

G

cytidine and dCMP deaminase domain containing 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CDADC1 mRNA

NCBI chr15:33,726,590...33,755,611
Ensembl chr15:33,723,435...33,755,576

G

cell division cycle 37, HSP90 cochaperone

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CDC37 mRNA

NCBI chr 8:19,677,400...19,690,761
Ensembl chr 8:19,671,938...19,690,809

G

cell division cycle 42

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CDC42 mRNA

NCBI chr 5:149,555,069...149,593,239
Ensembl chr 5:149,553,724...149,593,111

G

cyclin-dependent kinase 12

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CDK12 mRNA

NCBI chr10:83,201,177...83,256,906
Ensembl chr10:83,201,211...83,280,888
Ensembl chr10:83,201,211...83,280,888

G

cyclin-dependent kinase 4

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CDK4 mRNA

NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403

G

cyclin-dependent kinase inhibitor 1B

multiple interactions

[troglitazone co-treated with [Hydrochlorothiazide co-treated with Hydralazine co-treated with Reserpine]] results in decreased expression of CDKN1B protein

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

cyclin-dependent kinase inhibitor 2A

multiple interactions
decreases methylation

[Hydrochlorothiazide co-treated with Hydralazine co-treated with Reserpine] inhibits the reaction [Desoxycorticosterone Acetate affects the localization of CDKN2A protein]; [Hydrochlorothiazide co-treated with Hydralazine co-treated with Reserpine] inhibits the reaction [Desoxycorticosterone Acetate results in increased expression of CDKN2A mRNA]
Hydralazine results in decreased methylation of CDKN2A promoter

PMID:15862127 PMID:18504326

NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149

G

cerebellar degeneration-related protein 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CDR2 mRNA

NCBI chr 1:175,502,837...175,527,746
Ensembl chr 1:175,502,838...175,537,472

G

carboxyl ester lipase

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CEL mRNA

NCBI chr 3:11,883,532...11,891,035
Ensembl chr 3:11,883,532...11,891,035

G

centromere protein N

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CENPN mRNA

NCBI chr19:44,971,265...44,994,019
Ensembl chr19:44,968,308...44,994,012

G

ceramide synthase 5

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CERS5 mRNA

NCBI chr 7:130,859,993...130,897,979
Ensembl chr 7:130,859,990...130,897,947

G

cilia and flagella associated protein 300

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CFAP300 mRNA

NCBI chr 8:5,180,180...5,198,840
Ensembl chr 8:5,180,675...5,198,807

G

coiled-coil-helix-coiled-coil-helix domain containing 10

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CHCHD10 mRNA

NCBI chr20:12,725,839...12,727,638
Ensembl chr20:12,725,842...12,732,763

G

coiled-coil-helix-coiled-coil-helix domain containing 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CHCHD2 mRNA

NCBI chr12:26,828,738...26,834,762
Ensembl chr12:26,828,736...26,834,755

G

chromodomain helicase DNA binding protein 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CHD2 mRNA

NCBI chr 1:127,188,146...127,317,041
Ensembl chr 1:127,190,059...127,300,502

G

charged multivesicular body protein 5

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CHMP5 mRNA

NCBI chr 5:56,081,385...56,098,529
Ensembl chr 5:56,081,343...56,098,529

G

chimerin 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CHN2 mRNA

NCBI chr 4:83,148,616...83,407,711
Ensembl chr 4:83,147,983...83,407,709

G

cholinergic receptor nicotinic alpha 1 subunit

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CHRNA1 mRNA

NCBI chr 3:58,454,763...58,469,832
Ensembl chr 3:58,454,744...58,469,840

G

carbohydrate sulfotransferase 13

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CHST13 mRNA

NCBI chr 4:122,824,022...122,837,940
Ensembl chr 4:122,824,022...122,838,019

G

calcium and integrin binding 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CIB1 mRNA

NCBI chr 1:134,178,331...134,183,895
Ensembl chr 1:134,178,331...134,213,423

G

cytoplasmic linker associated protein 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CLASP2 mRNA

NCBI chr 8:113,677,345...113,859,957
Ensembl chr 8:113,677,284...113,858,731

G

chloride voltage-gated channel 5

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CLCN5 mRNA

NCBI chr X:15,185,380...15,339,977
Ensembl chr X:15,185,451...15,334,264

G

citramalyl-CoA lyase

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CLYBL mRNA

NCBI chr15:99,283,644...99,505,697
Ensembl chr15:99,283,650...99,505,695

G

cyclin and CBS domain divalent metal cation transport mediator 3

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CNNM3 mRNA

NCBI chr 9:38,755,374...38,770,740
Ensembl chr 9:38,755,390...38,770,740

G

cytochrome C oxidase assembly factor 3

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of COA3 mRNA

NCBI chr10:86,220,192...86,221,173
Ensembl chr10:86,220,194...86,221,178

G

component of oligomeric golgi complex 5

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of COG5 mRNA

NCBI chr 6:48,242,470...48,545,185
Ensembl chr 6:48,242,482...48,529,009

G

collagen type I alpha 1 chain

decreases expression
decreases expression
multiple interactions

Hydralazine results in decreased expression of COL1A1 mRNA
hydralazine decreases expression of Col1a1 mRNA in liver
[Hydralazine co-treated with Valproic Acid] results in increased expression of COL1A1 mRNA

CTD
RGD

PMID:8941590 PMID:17183730 PMID:33315911

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

collagen type IV alpha 6 chain

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of COL4A6 mRNA

NCBI chr X:104,766,463...105,117,499
Ensembl chr X:104,766,957...105,117,500

G

copper metabolism domain containing 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of COMMD1 mRNA

NCBI chr14:96,880,463...96,984,494
Ensembl chr14:96,880,463...96,984,501

G

COMM domain containing 6

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of COMMD6 mRNA

NCBI chr15:78,467,333...78,474,382
Ensembl chr15:78,467,804...78,474,382

G

COPI coat complex subunit epsilon

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of COPE mRNA

NCBI chr16:19,114,871...19,125,076
Ensembl chr16:19,114,871...19,128,907

G

COP9 signalosome subunit 4

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of COPS4 mRNA

NCBI chr14:9,078,579...9,108,788
Ensembl chr14:9,078,576...9,108,887

G

coenzyme Q4

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of COQ4 mRNA

NCBI chr 3:13,060,054...13,070,502
Ensembl chr 3:13,060,455...13,068,799

G

cytochrome c oxidase subunit 6B1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of COX6B1 mRNA

NCBI chr 1:85,875,080...85,884,081
Ensembl chr 1:85,875,109...85,884,001
Ensembl chr 2:85,875,109...85,884,001
Ensembl chr 5:85,875,109...85,884,001

G

cytochrome c oxidase subunit 7C

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of COX7C mRNA

NCBI chr 2:16,841,771...16,843,796
Ensembl chr 2:16,840,837...16,843,760

G

carnitine palmitoyltransferase 1A

multiple interactions

Hydralazine inhibits the reaction [AGT protein results in decreased expression of CPT1A mRNA]

NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055

G

cAMP responsive element binding protein 5

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CREB5 mRNA

NCBI chr 4:82,393,091...82,794,320
Ensembl chr 4:82,393,730...82,790,325

G

crystallin, beta A4

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CRYBA4 mRNA

NCBI chr12:44,378,734...44,393,226
Ensembl chr12:44,378,737...44,393,221

G

CCCTC-binding factor

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in decreased expression of CTCF mRNA

NCBI chr19:33,521,726...33,571,124
Ensembl chr19:33,529,319...33,571,123

G

catenin delta 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CTNND1 mRNA

NCBI chr 3:69,683,328...69,734,550
Ensembl chr 3:69,683,313...69,734,516

G

cathepsin K

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CTSK mRNA

NCBI chr 2:183,058,586...183,069,551
Ensembl chr 2:183,058,569...183,069,550

G

CUE domain containing 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CUEDC2 mRNA

NCBI chr 1:245,192,057...245,200,594
Ensembl chr 1:245,192,063...245,200,339

G

cullin 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CUL1 mRNA

NCBI chr 4:76,551,952...76,625,830
Ensembl chr 4:76,551,983...76,627,980

G

cytochrome b5 reductase 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CYB5R1 mRNA

NCBI chr13:45,849,017...45,855,458
Ensembl chr13:45,849,091...45,855,458

G

cytochrome b5 reductase 3

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CYB5R3 mRNA

NCBI chr 7:114,306,686...114,324,247
Ensembl chr 7:114,306,685...114,324,298

G

cytoplasmic FMR1 interacting protein 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CYFIP2 mRNA

NCBI chr10:30,621,318...30,741,113
Ensembl chr10:30,621,318...30,741,113

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions

Hydralazine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions

Hydralazine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A2 protein]

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 2, subfamily a, polypeptide 3

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CYP2A7 mRNA

NCBI chr 1:82,171,914...82,179,980
Ensembl chr 1:82,169,949...82,179,979

G

cytochrome P450, family 4, subfamily x, polypeptide 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CYP4X1 mRNA

NCBI chr 5:128,651,681...128,683,338
Ensembl chr 5:128,651,776...128,682,779

G

dishevelled-binding antagonist of beta-catenin 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of DACT2 mRNA

NCBI chr 1:55,181,023...55,191,026
Ensembl chr 1:55,181,024...55,191,096

G

differentiation antagonizing non-protein coding RNA

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of DANCR mRNA

NCBI chr14:34,126,956...34,127,936

G

death associated protein kinase 1

decreases methylation
increases expression

Hydralazine results in decreased methylation of DAPK1 promoter
Hydralazine results in increased expression of DAPK1 mRNA

NCBI chr17:3,930,223...4,090,991
Ensembl chr17:3,930,213...4,090,991

G

DBF4B-CDC7 kinase regulatory subunit

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of DBF4B mRNA

NCBI chr10:87,713,805...87,719,197

G

diazepam binding inhibitor

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of DBI mRNA

NCBI chr13:31,241,466...31,249,853
Ensembl chr13:31,206,988...31,268,693

G

DDB1 and CUL4 associated factor 8

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of DCAF8 mRNA

NCBI chr13:84,609,838...84,667,025
Ensembl chr13:84,610,248...84,669,726

G

DNA cross-link repair 1C

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of DCLRE1C mRNA

NCBI chr17:74,775,828...74,810,089
Ensembl chr17:74,776,935...74,809,186

G

decapping mRNA 1A

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of DCP1A mRNA

NCBI chr16:5,656,960...5,702,151
Ensembl chr16:5,656,773...5,702,140

G

DNA-damage inducible transcript 3

multiple interactions

Hydralazine inhibits the reaction [Ethanol results in increased expression of DDIT3 mRNA]; Hydralazine inhibits the reaction [Ethanol results in increased expression of DDIT3 protein]

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

D-dopachrome tautomerase

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of DDT mRNA

NCBI chr20:12,884,216...12,886,687
Ensembl chr20:12,884,243...12,888,482

G

DEAD-box helicase 27

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of DDX27 mRNA

NCBI chr 3:155,744,182...155,763,380
Ensembl chr 3:155,744,150...155,763,372

G

DEAD-box helicase 46

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of DDX46 mRNA

NCBI chr17:8,942,070...8,988,440
Ensembl chr17:8,944,454...8,988,439

G

dihydrolipoamide S-acetyltransferase

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in decreased expression of DLAT mRNA

NCBI chr 8:50,979,151...51,004,435
Ensembl chr 8:50,978,051...51,004,479
Ensembl chr 1:50,978,051...51,004,479

G

dynein, axonemal, assembly factor 5

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in decreased expression of DNAAF5 mRNA

NCBI chr12:15,453,636...15,492,722
Ensembl chr12:15,453,636...15,492,739

G

dynein axonemal heavy chain 14

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of DNAH14 mRNA

NCBI chr13:93,322,653...93,540,706
Ensembl chr13:93,322,711...93,538,646

G

DnaJ heat shock protein family (Hsp40) member A3

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of DNAJA3 mRNA

NCBI chr10:10,854,732...10,880,171
Ensembl chr10:10,854,732...10,880,161

G

DnaJ heat shock protein family (Hsp40) member C3

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of DNAJC3 mRNA

NCBI chr15:96,025,605...96,068,585
Ensembl chr15:96,025,624...96,065,181

G

DnaJ heat shock protein family (Hsp40) member C8

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of DNAJC8 mRNA

NCBI chr 5:144,745,055...144,763,106
Ensembl chr 5:144,745,036...144,763,108

G

dynein heavy chain domain 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of DNHD1 mRNA

NCBI chr 1:159,990,785...160,077,990
Ensembl chr 1:159,990,438...160,074,858

G

dpy-19 like C-mannosyltransferase 3

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of DPY19L3 mRNA

NCBI chr 1:88,350,303...88,417,339
Ensembl chr 1:88,350,303...88,417,339

G

dopamine receptor D4

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of DRD4 mRNA

NCBI chr 1:196,396,366...196,400,824
Ensembl chr 1:196,396,366...196,399,553

G

DNA replication and sister chromatid cohesion 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of DSCC1 mRNA

NCBI chr 7:86,482,588...86,498,212
Ensembl chr 7:86,482,588...86,498,212

G

dynein cytoplasmic 1 light intermediate chain 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of DYNC1LI1 mRNA

NCBI chr 8:114,376,649...114,410,297
Ensembl chr 8:114,376,662...114,410,934

G

dynein light chain LC8-type 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of DYNLL1 mRNA

NCBI chr12:41,312,365...41,316,157
Ensembl chr12:41,312,367...41,314,741

G

endothelin 1

multiple interactions

Hydralazine inhibits the reaction [Nitric Oxide deficiency results in increased expression of EDN1 mRNA]

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

G

eukaryotic translation elongation factor 1 delta

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of EEF1D mRNA

NCBI chr 7:107,581,930...107,596,735
Ensembl chr 7:107,581,930...107,608,799

G

EF hand domain family, member B

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of EFHB mRNA

NCBI chr 9:6,372,191...6,441,678
Ensembl chr 9:6,372,194...6,441,919

G

EF-hand domain family, member D2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of EFHD2 mRNA

NCBI chr 5:154,160,945...154,176,980
Ensembl chr 5:154,160,946...154,176,980

G

euchromatic histone lysine methyltransferase 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of EHMT2 mRNA

NCBI chr20:3,919,623...3,936,751
Ensembl chr20:3,919,624...3,941,547

G

eukaryotic translation initiation factor 3, subunit L

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of EIF3L mRNA

NCBI chr 7:110,652,565...110,663,614
Ensembl chr 7:110,627,107...110,663,614

G

eukaryotic translation initiation factor 4B

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of EIF4B mRNA

NCBI chr 7:133,206,637...133,228,436

G

eukaryotic translation initiation factor 4 gamma, 3

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of EIF4G3 mRNA

NCBI chr 5:150,197,410...150,418,862
Ensembl chr 5:150,195,226...150,418,363

G

ETS transcription factor ELK3

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ELK3 mRNA

NCBI chr 7:27,768,582...27,831,088
Ensembl chr 7:27,768,599...27,804,084

G

elongation factor for RNA polymerase II

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ELL mRNA

NCBI chr16:18,843,775...18,891,484
Ensembl chr16:18,843,780...18,891,118

G

elongation factor for RNA polymerase II 3

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in decreased expression of ELL3 mRNA

NCBI chr 3:108,413,035...108,417,181
Ensembl chr 3:108,410,448...108,417,132

G

elastin

multiple interactions

[Isoproterenol co-treated with Hydralazine] results in increased expression of ELN protein

NCBI chr12:21,968,544...22,011,929
Ensembl chr12:21,968,544...22,011,928

G

elongin B

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ELOB mRNA

NCBI chr10:12,848,830...12,853,897
Ensembl chr10:12,848,827...12,853,635

G

ELOVL fatty acid elongase 6

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ELOVL6 mRNA

NCBI chr 2:218,063,682...218,174,767
Ensembl chr 2:218,063,804...218,171,186

G

epithelial membrane protein 3

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of EMP3 mRNA

NCBI chr 1:96,388,651...96,391,946
Ensembl chr 1:96,388,652...96,391,988

G

endothelial PAS domain protein 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of EPAS1 mRNA

NCBI chr 6:7,790,236...7,871,717
Ensembl chr 6:7,790,647...7,871,228

G

enhancer of polycomb homolog 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of EPC1 mRNA

NCBI chr17:54,503,358...54,594,444
Ensembl chr17:54,503,358...54,594,425

G

Eph receptor A8

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of EPHA8 mRNA

NCBI chr 5:149,166,107...149,193,515
Ensembl chr 5:149,166,697...149,193,399

G

epsin 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of EPN2 mRNA

NCBI chr10:46,197,785...46,259,673
Ensembl chr10:46,197,785...46,259,642

G

glutamyl-prolyl-tRNA synthetase 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of EPRS1 mRNA

NCBI chr13:96,901,548...96,971,966
Ensembl chr13:96,901,575...96,971,966

G

endoplasmic reticulum lectin 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ERLEC1 mRNA

NCBI chr14:104,655,745...104,693,508
Ensembl chr14:104,655,673...104,693,480

G

endoplasmic reticulum oxidoreductase 1 beta

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ERO1B mRNA

NCBI chr17:85,861,086...86,003,244
Ensembl chr17:85,929,618...86,003,398

G

estrogen receptor 1

decreases methylation
multiple interactions
increases expression

Hydralazine results in decreased methylation of ESR1 promoter
Hydralazine inhibits the reaction [3-methylquinoline results in increased activity of ESR1 protein]; Hydralazine inhibits the reaction [8-methylquinoline results in increased activity of ESR1 protein]
Hydralazine results in increased expression of ESR1 mRNA

PMID:15862127 PMID:30896932

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

enhancer trap locus 4

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of KIAA1217 mRNA

NCBI chr17:82,841,075...83,304,868
Ensembl chr17:82,495,041...83,304,715

G

exocyst complex component 3-like 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of EXOC3L2 mRNA

NCBI chr 1:79,113,784...79,145,359
Ensembl chr 1:79,112,506...79,145,465

G

exocyst complex component 7

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of EXOC7 mRNA

NCBI chr10:101,521,630...101,540,425
Ensembl chr10:101,520,927...101,540,561

G

F11 receptor

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of F11R mRNA

NCBI chr13:83,873,797...83,897,388
Ensembl chr13:83,873,797...83,897,402

G

coagulation factor XII

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of F12 mRNA

NCBI chr17:9,207,683...9,215,530
Ensembl chr17:9,207,683...9,215,530

G

family with sequence similarity 120 member A

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of FAM120A mRNA

NCBI chr17:15,684,233...15,774,964
Ensembl chr17:15,684,233...15,774,964

G

family with sequence similarity 13, member B

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of FAM13B mRNA

NCBI chr18:26,040,285...26,107,112
Ensembl chr18:26,040,285...26,106,587

G

family with sequence similarity 162, member A

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of FAM162A mRNA

NCBI chr11:64,680,978...64,709,865
Ensembl chr11:64,680,323...64,711,239

G

family with sequence similarity 163, member A

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in decreased expression of FAM163A mRNA

NCBI chr13:68,262,867...68,341,323
Ensembl chr13:68,262,872...68,341,049

G

family with sequence similarity 210, member B

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of FAM210B mRNA

NCBI chr 3:161,118,228...161,128,400
Ensembl chr 3:161,118,239...161,128,397

G

family with sequence similarity 241 member B

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of FAM241B mRNA

NCBI chr20:30,052,315...30,055,247
Ensembl chr20:30,052,324...30,055,084
Ensembl chr 6:30,052,324...30,055,084

G

FAM3 metabolism regulating signaling molecule A

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of FAM3A mRNA

NCBI chr X:152,166,716...152,175,327
Ensembl chr X:152,165,535...152,175,362

G

family with sequence similarity 50, member A

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of FAM50A mRNA

NCBI chr X:152,095,245...152,102,362
Ensembl chr X:152,095,245...152,102,362

G

Fas ligand

multiple interactions

Hydralazine inhibits the reaction [Acrolein promotes the reaction [RELA protein binds to FASLG promoter]]; Hydralazine inhibits the reaction [Acrolein promotes the reaction [Zidovudine promotes the reaction [RELA protein binds to FASLG promoter]]]; Hydralazine inhibits the reaction [Acrolein promotes the reaction [Zidovudine results in increased expression of FASLG mRNA]]; Hydralazine inhibits the reaction [Acrolein results in increased expression of FASLG mRNA]; Hydralazine inhibits the reaction [Zidovudine promotes the reaction [Acrolein promotes the reaction [RELA protein binds to FASLG promoter]]]; Hydralazine inhibits the reaction [Zidovudine promotes the reaction [Acrolein results in increased expression of FASLG mRNA]]; Hydralazine inhibits the reaction [Zidovudine promotes the reaction [RELA protein binds to FASLG promoter]]; Hydralazine inhibits the reaction [Zidovudine results in increased expression of FASLG mRNA]
Hydralazine inhibits the reaction [Acrolein promotes the reaction [Zidovudine results in increased expression of FASLG mRNA]]; Hydralazine inhibits the reaction [Acrolein results in increased expression of FASLG mRNA]; Hydralazine inhibits the reaction [Zidovudine promotes the reaction [Acrolein results in increased expression of FASLG mRNA]]; Hydralazine inhibits the reaction [Zidovudine results in increased expression of FASLG mRNA]

NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215

G

fibrosin-like 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of FBRSL1 mRNA

NCBI chr12:46,231,466...46,320,607
Ensembl chr12:46,231,495...46,320,357

G

F-box and WD repeat domain containing 4

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of FBXW4 mRNA

NCBI chr 1:244,426,892...244,514,188
Ensembl chr 1:244,426,896...244,514,163

G

farnesyl diphosphate synthase

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of FDPS mRNA

NCBI chr 2:174,497,402...174,507,031
Ensembl chr 2:174,486,665...174,507,776

G

free fatty acid receptor 3

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of FFAR3 mRNA

NCBI chr 1:86,105,388...86,106,728
Ensembl chr 1:86,104,920...86,106,849

G

fragile histidine triad diadenosine triphosphatase

decreases methylation
increases expression

Hydralazine results in decreased methylation of FHIT promoter
Hydralazine results in increased expression of FHIT mRNA

NCBI chr15:13,935,029...15,442,620
Ensembl chr15:13,934,995...15,442,340

G

fission, mitochondrial 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of FIS1 mRNA

NCBI chr12:19,708,560...19,723,392
Ensembl chr12:19,708,558...19,723,377

G

flotillin 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of FLOT1 mRNA

NCBI chr20:2,917,864...2,927,993
Ensembl chr20:2,917,137...2,927,978

G

Fms related receptor tyrosine kinase 1

multiple interactions

[Hydralazine co-treated with Hydrochlorothiazide] inhibits the reaction [Cyclosporine results in increased expression of FLT1 mRNA]

NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626

G

Fos proto-oncogene, AP-1 transcription factor subunit

affects expression

Hydralazine affects the expression of FOS protein

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

forkhead box P1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of FOXP1 mRNA

NCBI chr 4:131,559,599...132,155,092
Ensembl chr 4:131,564,756...132,112,258

G

forkhead box P2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in decreased expression of FOXP2 mRNA

NCBI chr 4:43,133,827...43,712,442
Ensembl chr 4:43,133,912...43,711,683

G

forkhead box P3

increases expression

Hydralazine results in increased expression of FOXP3 protein

NCBI chr X:14,908,494...14,924,994
Ensembl chr X:14,908,494...14,923,838

G

follistatin

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of FST mRNA

NCBI chr 2:46,123,260...46,130,584
Ensembl chr 2:46,123,439...46,130,571

G

follistatin-like 5

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of FSTL5 mRNA

NCBI chr 2:160,857,989...161,526,589
Ensembl chr 2:160,856,291...161,526,589

G

ferritin heavy chain 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of FTH1 mRNA

NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424

G

ferritin, heavy polypeptide-like 17, member A

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of FTHL17 mRNA

NCBI chr X:49,595,422...49,596,399
Ensembl chr X:49,595,718...49,596,266

G

FXYD domain-containing ion transport regulator 5

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of FXYD5 mRNA

NCBI chr 1:86,267,937...86,277,329
Ensembl chr 1:86,267,406...86,277,519

G

GABA type A receptor-associated protein

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of GABARAP mRNA

NCBI chr10:54,714,777...54,718,099
Ensembl chr10:54,714,198...54,717,765

G

polypeptide N-acetylgalactosaminyltransferase 7

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of GALNT7 mRNA

NCBI chr16:32,578,643...32,703,189
Ensembl chr16:32,578,690...32,702,690

G

galanin-like peptide

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of GALP mRNA

NCBI chr 1:67,684,023...67,703,121
Ensembl chr 1:67,684,025...67,702,269

G

guanidinoacetate N-methyltransferase

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of GAMT mRNA

NCBI chr 7:9,448,590...9,451,413
Ensembl chr 7:9,448,628...9,451,778

G

glucosidase II alpha subunit

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of GANAB mRNA

NCBI chr 1:205,793,910...205,813,704
Ensembl chr 1:205,793,895...205,813,695

G

glutamine amidotransferase class 1 domain containing 3A

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of GATD3 mRNA

NCBI chr20:10,514,793...10,522,894
Ensembl chr20:10,514,744...10,522,885

G

GDNF family receptor alpha 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of GFRA2 mRNA

NCBI chr15:45,941,841...46,033,715
Ensembl chr15:45,941,828...46,033,714

G

GDNF family receptor alpha 3

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of GFRA3 mRNA

NCBI chr18:26,297,828...26,326,105
Ensembl chr18:26,297,829...26,326,105

G

gap junction protein, delta 4

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of GJD4 mRNA

NCBI chr17:57,348,844...57,352,601
Ensembl chr17:57,349,877...57,352,446

G

galactosidase, alpha

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of GLA mRNA

NCBI chr X:97,769,227...97,780,646
Ensembl chr X:97,768,996...97,780,664

G

glyceronephosphate O-acyltransferase

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of GNPAT mRNA

NCBI chr19:52,822,326...52,848,872
Ensembl chr19:52,822,319...52,852,361

G

golgin B1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of GOLGB1 mRNA

NCBI chr11:63,843,179...63,900,665
Ensembl chr11:63,843,986...63,900,770

G

golgi membrane protein 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of GOLM2 mRNA

NCBI chr 3:108,827,017...108,896,207
Ensembl chr 3:108,827,047...108,896,207

G

glycoprotein 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of GP2 mRNA

NCBI chr 1:173,797,057...173,812,619
Ensembl chr 1:173,797,057...173,812,619

G

glycosylphosphatidylinositol anchor attachment 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in decreased expression of GPAA1 mRNA

NCBI chr 7:108,051,896...108,055,479
Ensembl chr 7:108,051,861...108,055,484

G

GC-rich promoter binding protein 1-like 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of GPBP1L1 mRNA

NCBI chr 5:130,009,768...130,050,636
Ensembl chr 5:130,023,137...130,050,459

G

G protein-coupled receptor 83

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of GPR83 mRNA

NCBI chr 8:11,693,540...11,704,028
Ensembl chr 8:11,693,540...11,704,028

G

G protein pathway suppressor 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of GPS2 mRNA

NCBI chr10:54,637,360...54,640,542
Ensembl chr10:54,637,455...54,640,650

G

glutamic--pyruvic transaminase

multiple interactions

Hydralazine inhibits the reaction [Ethanol results in increased expression of GPT protein]

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

GRB2-related adaptor protein

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of GRAP mRNA

NCBI chr10:46,298,965...46,352,057
Ensembl chr10:46,332,909...46,352,056

G

G protein-coupled receptor kinase 3

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in decreased expression of GRK3 mRNA

NCBI chr12:43,624,778...43,735,375
Ensembl chr12:43,624,897...43,731,262

G

G protein-coupled receptor kinase 4

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of GRK4 mRNA

NCBI chr14:75,998,554...76,080,808
Ensembl chr14:76,006,218...76,080,693

G

glutamate-rich WD repeat containing 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of GRWD1 mRNA

NCBI chr 1:96,301,260...96,306,962
Ensembl chr 1:96,301,261...96,307,201

G

gelsolin

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of GSN mRNA

NCBI chr 3:18,585,166...18,638,404
Ensembl chr 3:18,585,172...18,638,402

G

glutathione S-transferase pi 1

decreases methylation
increases expression

Hydralazine results in decreased methylation of GSTP1 promoter
Hydralazine results in increased expression of GSTP1 mRNA

NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226

G

glutathione S-transferase theta 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of GSTT2 mRNA

NCBI chr20:12,819,617...12,823,288
Ensembl chr20:12,819,170...12,823,288

G

guanylate kinase 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of GUK1 mRNA

NCBI chr10:43,971,514...43,988,658
Ensembl chr10:43,971,509...43,980,107

G

H3.3 histone A

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of H3-3A mRNA

NCBI chr13:92,533,289...92,544,902
Ensembl chr13:92,533,298...92,544,908

G

3-hydroxyanthranilate 3,4-dioxygenase

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of HAAO mRNA

NCBI chr 6:10,845,235...10,864,863
Ensembl chr 6:10,845,771...10,864,877

G

hemoglobin alpha, adult chain 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in decreased expression of HBA1 mRNA

NCBI chr10:15,323,830...15,324,677
Ensembl chr10:15,307,815...15,338,392
Ensembl chr10:15,307,815...15,338,392

G

hemoglobin subunit beta

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in decreased expression of HBB mRNA

NCBI chr 1:158,250,421...158,251,832
Ensembl chr 1:158,120,200...158,252,012

G

hemoglobin subunit zeta

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in decreased expression of HBZ mRNA

NCBI chr10:15,343,821...15,345,301
Ensembl chr10:15,343,831...15,345,312

G

host cell factor C1 regulator 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of HCFC1R1 mRNA

NCBI chr10:12,705,139...12,706,852
Ensembl chr10:12,705,077...12,706,850

G

HDGF like 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of HDGFL1 mRNA

NCBI chr17:38,207,906...38,209,902

G

HEAT repeat containing 5B

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in decreased expression of HEATR5B mRNA

NCBI chr 6:16,243,424...16,323,444
Ensembl chr 6:16,243,461...16,323,435

G

heme binding protein 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of HEBP1 mRNA

NCBI chr 4:167,974,316...168,003,854
Ensembl chr 4:167,974,319...168,003,854

G

HEN methyltransferase 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of HENMT1 mRNA

NCBI chr 2:196,585,732...196,603,700
Ensembl chr 2:196,586,797...196,599,738

G

homeostatic iron regulator

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of HFE mRNA

NCBI chr17:41,413,451...41,421,502
Ensembl chr17:41,413,451...41,421,502

G

HIG1 hypoxia inducible domain family, member 2A

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of HIGD2A mRNA

NCBI chr17:10,021,853...10,022,777
Ensembl chr17:10,021,859...10,022,796

G

histone H4 transcription factor

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of HINFP mRNA

NCBI chr 8:44,634,333...44,644,288
Ensembl chr 8:44,634,333...44,641,000

G

histidine triad nucleotide binding protein 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of HINT1 mRNA

NCBI chr10:38,989,516...38,993,259
Ensembl chr 4:92,100,973...92,101,568

G

histidine triad nucleotide binding protein 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of HINT2 mRNA

NCBI chr 5:57,904,613...57,906,868
Ensembl chr 5:57,904,614...57,907,097

G

hexokinase 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of HK1 mRNA

NCBI chr20:30,230,488...30,332,099
Ensembl chr20:30,230,486...30,332,131

G

3-hydroxy-3-methylglutaryl-CoA lyase

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of HMGCL mRNA

NCBI chr 5:148,178,203...148,192,072
Ensembl chr 5:148,178,252...148,192,068

G

HMG-box containing 4

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of HMGXB4 mRNA

NCBI chr19:13,364,741...13,403,563
Ensembl chr19:13,364,807...13,403,563

G

heme oxygenase 1

multiple interactions

Hydralazine inhibits the reaction [[Acrolein binds to ALB protein] which results in increased expression of HMOX1 mRNA]

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

HPS3, biogenesis of lysosomal organelles complex 2 subunit 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of HPS3 mRNA

NCBI chr 2:102,484,574...102,527,580
Ensembl chr 2:102,484,574...102,526,047

G

heparanase

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of HPSE mRNA

NCBI chr14:8,896,593...8,937,011
Ensembl chr14:8,896,593...8,937,010

G

heat shock factor binding protein 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of HSBP1 mRNA

NCBI chr19:47,401,039...47,405,373
Ensembl chr19:47,400,966...47,435,821

G

heat shock protein family A (Hsp70) member 5

multiple interactions

Hydralazine inhibits the reaction [Ethanol results in increased expression of HSPA5 mRNA]

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

heat shock protein family A (Hsp70) member 8

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of HSPA8 mRNA

NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259

G

hydroxypyruvate isomerase

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of HYI mRNA

NCBI chr 5:131,894,575...131,897,709
Ensembl chr 5:131,894,598...131,897,251

G

intercellular adhesion molecule 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ICAM1 mRNA

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

isoprenylcysteine carboxyl methyltransferase

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ICMT mRNA

NCBI chr 5:162,804,368...162,811,129
Ensembl chr 5:162,804,368...162,811,128

G

isocitrate dehydrogenase (NAD(+)) 3 non-catalytic subunit gamma

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of IDH3G mRNA

NCBI chr X:151,515,244...151,524,175
Ensembl chr X:151,515,247...151,524,171

G

interferon induced transmembrane protein 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of IFITM2 mRNA

NCBI chr 1:196,051,539...196,052,719
Ensembl chr 1:196,051,537...196,052,741

G

interferon-related developmental regulator 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of IFRD1 mRNA

NCBI chr 6:57,269,395...57,317,833
Ensembl chr 6:57,269,384...57,288,990

G

intraflagellar transport 22

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of IFT22 mRNA

NCBI chr12:19,759,072...19,768,859
Ensembl chr12:19,761,790...19,768,809

G

intraflagellar transport 57

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of IFT57 mRNA

NCBI chr11:51,051,520...51,124,909
Ensembl chr11:51,059,611...51,124,812

G

immunoglobulin binding protein 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of IGBP1 mRNA

NCBI chr X:65,582,832...65,605,078
Ensembl chr X:65,582,821...65,606,049

G

insulin-like growth factor 2 mRNA binding protein 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of IGF2BP2 mRNA

NCBI chr11:78,874,402...78,974,392
Ensembl chr11:78,874,414...78,974,377

G

interleukin 10

increases secretion

Hydralazine results in increased secretion of IL10 protein

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 1 receptor accessory protein-like 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of IL1RAPL2 mRNA

NCBI chr X:100,961,509...102,271,753
Ensembl chr X:100,961,812...102,271,753

G

interleukin 3

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in decreased expression of IL3 mRNA

NCBI chr10:38,405,716...38,408,066
Ensembl chr10:38,405,716...38,408,066

G

interleukin 6

decreases secretion
increases expression

Hydralazine results in decreased secretion of IL6 protein
Hydralazine results in increased expression of IL6 protein

PMID:16612254 PMID:19575532

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

innate immunity activator

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of INAVA mRNA

NCBI chr13:47,666,446...47,687,383
Ensembl chr13:47,666,447...47,686,729

G

INO80 complex subunit E

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of INO80E mRNA

NCBI chr 1:181,461,406...181,472,059
Ensembl chr 1:181,461,408...181,472,469

G

interferon regulatory factor 7

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of IRF7 mRNA

NCBI chr 1:196,367,380...196,370,943
Ensembl chr 1:196,367,361...196,370,832

G

iroquois homeobox 3

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of IRX3 mRNA

NCBI chr19:15,211,882...15,215,317
Ensembl chr19:15,211,878...15,215,317

G

iron-sulfur cluster assembly 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ISCA2 mRNA

NCBI chr 6:104,418,509...104,420,019
Ensembl chr 6:104,418,454...104,420,045
Ensembl chr14:104,418,454...104,420,045

G

integrin subunit alpha M

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in decreased expression of ITGAM mRNA

NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503

G

intersectin 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ITSN1 mRNA

NCBI chr11:30,978,590...31,160,645
Ensembl chr11:30,978,590...31,160,645

G

intersectin 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ITSN2 mRNA

NCBI chr 6:27,616,645...27,727,373
Ensembl chr 6:27,600,406...27,727,124

G

jumonji and AT-rich interaction domain containing 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of JARID2 mRNA

NCBI chr17:19,777,487...19,957,696
Ensembl chr17:19,777,266...19,955,690

G

jumonji domain containing 1C

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of JMJD1C mRNA

NCBI chr20:21,332,147...21,494,220
Ensembl chr20:21,332,147...21,463,122

G

KN motif and ankyrin repeat domains 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of KANK1 mRNA

NCBI chr 1:222,877,962...223,074,514
Ensembl chr 1:222,877,622...223,074,514

G

KN motif and ankyrin repeat domains 4

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of KANK4 mRNA

NCBI chr 5:113,401,491...113,465,526
Ensembl chr 5:113,402,468...113,465,555

G

potassium voltage-gated channel subfamily A member 7

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in decreased expression of KCNA7 mRNA

NCBI chr 1:95,886,073...95,891,565
Ensembl chr 1:95,886,073...95,891,565

G

KDEL endoplasmic reticulum protein retention receptor 3

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of KDELR3 mRNA

NCBI chr 7:111,079,236...111,089,463
Ensembl chr 7:111,079,218...111,101,600

G

KIAA0586 homolog

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of KIAA0586 mRNA

NCBI chr 6:89,622,711...89,725,951
Ensembl chr 6:89,623,699...89,725,962

G

KLF transcription factor 6

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of KLF6 mRNA

NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570

G

kelch-like family member 9

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of KLHL9 mRNA

NCBI chr 5:103,333,747...103,337,931

G

keratin 17

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in decreased expression of KRT17 mRNA

NCBI chr10:85,178,673...85,183,392
Ensembl chr10:85,178,675...85,183,392

G

LIM and SH3 protein 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of LASP1 mRNA

NCBI chr10:82,795,177...82,835,659
Ensembl chr10:82,795,137...82,943,292

G

lymphoid enhancer binding factor 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of LEF1 mRNA

NCBI chr 2:219,666,549...219,779,815
Ensembl chr 2:219,666,592...219,779,794

G

galectin 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of LGALS1 mRNA

NCBI chr 7:110,485,239...110,488,345
Ensembl chr 7:110,481,392...110,488,345

G

galectin 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of LGALS2 mRNA

NCBI chr 7:110,403,171...110,410,046
Ensembl chr 7:110,403,173...110,404,802

G

leucine-rich repeat-containing G protein-coupled receptor 4

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of LGR4 mRNA

NCBI chr 3:96,447,385...96,550,006
Ensembl chr 3:96,447,858...96,548,899

G

LHFPL tetraspan subfamily member 5

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of LHFPL5 mRNA

NCBI chr20:6,632,324...6,642,534
Ensembl chr20:6,632,362...6,642,532

G

lin-37 DREAM MuvB core complex component

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of LIN37 mRNA

NCBI chr 1:85,809,065...85,813,235
Ensembl chr 1:85,809,074...85,812,991

G

epididymal secretory protein E3-beta-like

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of EDDM3A mRNA

NCBI chr15:24,385,585...24,386,643
Ensembl chr15:24,386,192...24,386,623

G

lysophosphatidylcholine acyltransferase 4

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of LPCAT4 mRNA

NCBI chr 3:99,044,729...99,052,963
Ensembl chr 3:99,044,729...99,052,875

G

lysophosphatidylglycerol acyltransferase 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of LPGAT1 mRNA

NCBI chr13:103,294,622...103,365,372
Ensembl chr13:103,294,528...103,362,333

G

lipin 3

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of LPIN3 mRNA

NCBI chr 3:149,533,719...149,558,494
Ensembl chr 3:149,534,051...149,558,327

G

LIM domain containing preferred translocation partner in lipoma

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of LPP mRNA

NCBI chr11:75,787,326...76,426,646
Ensembl chr11:75,797,078...76,422,597

G

leucine rich repeat and fibronectin type III domain containing 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of LRFN1 mRNA

NCBI chr 1:83,742,442...83,761,450
Ensembl chr 1:83,682,964...83,761,449

G

LDL receptor related protein 10

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of LRP10 mRNA

NCBI chr15:27,921,335...27,927,507
Ensembl chr15:27,920,259...27,927,505

G

leucine rich repeat containing 40

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of LRRC40 mRNA

NCBI chr 2:247,101,518...247,131,061
Ensembl chr 2:247,101,500...247,131,059

G

leucine rich repeat containing 8 VRAC subunit E

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of LRRC8E mRNA

NCBI chr12:2,578,240...2,589,407
Ensembl chr12:2,578,315...2,589,412

G

LUC7-like 3 pre-mRNA splicing factor

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of CROP mRNA

NCBI chr10:79,240,050...79,276,555
Ensembl chr10:79,240,563...79,276,538

G

lymphocyte antigen 86

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of LY86 mRNA

NCBI chr17:27,415,807...27,499,695
Ensembl chr17:27,415,830...27,487,260

G

monoamine oxidase A

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of MAOA mRNA

NCBI chr X:6,032,172...6,098,308
Ensembl chr X:6,030,795...6,099,593

G

mitogen activated protein kinase kinase 3

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of MAP2K3 mRNA

NCBI chr10:45,608,145...45,629,492
Ensembl chr10:45,607,163...45,629,492

G

mitogen activated protein kinase 1

multiple interactions

Hydralazine inhibits the reaction [AGT protein modified form results in increased phosphorylation of MAPK1 protein]

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

Hydralazine inhibits the reaction [AGT protein modified form results in increased phosphorylation of MAPK3 protein]

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

microtubule affinity regulating kinase 3

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of MARK3 mRNA

NCBI chr 6:130,626,612...130,716,245
Ensembl chr 6:130,627,482...130,716,647

G

MAS1 proto-oncogene, G protein-coupled receptor

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of MAS1 mRNA

NCBI chr 1:47,879,956...47,911,500
Ensembl chr 1:47,880,309...47,911,709

G

methyl-CpG binding domain protein 6

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of MBD6 mRNA

NCBI chr 7:63,107,562...63,115,841
Ensembl chr 7:63,107,562...63,113,274

G

membrane bound O-acyltransferase domain containing 7

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of MBOAT7 mRNA

NCBI chr 1:65,525,206...65,539,538
Ensembl chr 1:65,525,213...65,539,538

G

malic enzyme 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ME2 mRNA

NCBI chr18:67,350,833...67,400,987
Ensembl chr18:67,355,795...67,400,987

G

mediator complex subunit 8

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of MED8 mRNA

NCBI chr 5:131,948,632...131,949,516
Ensembl chr 5:131,943,982...131,950,305

G

methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of METTL3 mRNA

NCBI chr15:25,002,505...25,014,097
Ensembl chr15:25,003,172...25,014,041

G

methyltransferase 6, tRNA N3-cytidine

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of METTL6 mRNA

NCBI chr16:6,683,820...6,699,013
Ensembl chr16:6,583,465...6,698,975

G

major facilitator superfamily domain containing 5

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of MFSD5 mRNA

NCBI chr 7:133,409,096...133,411,377
Ensembl chr 7:133,402,537...133,411,396

G

alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of MGAT1 mRNA

NCBI chr10:33,563,642...33,582,718
Ensembl chr10:33,561,388...33,591,503

G

O-6-methylguanine-DNA methyltransferase

decreases methylation
increases expression

Hydralazine results in decreased methylation of MGMT promoter
Hydralazine results in increased expression of MGMT mRNA

NCBI chr 1:191,710,980...191,937,760
Ensembl chr 1:191,710,930...191,937,756

G

matrix Gla protein

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of MGP mRNA

NCBI chr 4:169,766,290...169,769,612
Ensembl chr 4:169,766,279...169,769,667

G

microtubule associated monooxygenase, calponin and LIM domain containing 3

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of MICAL3 mRNA

NCBI chr 4:154,152,776...154,353,274
Ensembl chr 4:154,153,834...154,302,590

G

mitochondrial contact site and cristae organizing system subunit 13

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of MICOS13 mRNA

NCBI chr 9:1,439,841...1,441,782
Ensembl chr 9:1,439,058...1,442,076

G

MIS12 kinetochore complex component

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of MIS12 mRNA

NCBI chr10:55,739,741...55,747,915
Ensembl chr10:55,739,564...55,751,068

G

MKS transition zone complex subunit 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of MKS1 mRNA

NCBI chr10:72,655,921...72,667,007
Ensembl chr10:72,655,921...72,666,655

G

MLLT10, histone lysine methyltransferase DOT1L cofactor

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of MLLT10 mRNA

NCBI chr17:80,821,870...80,949,349
Ensembl chr17:80,822,556...80,949,345

G

metabolism of cobalamin associated B

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of MMAB mRNA

NCBI chr12:42,159,109...42,172,518
Ensembl chr12:42,159,089...42,172,490

G

membrane metallo-endopeptidase

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of MME mRNA

NCBI chr 2:147,686,913...147,803,808
Ensembl chr 2:147,722,086...147,803,792

G

matrix metallopeptidase 10

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of MMP10 mRNA

NCBI chr 8:4,689,840...4,697,748
Ensembl chr 8:4,689,840...4,697,748

G

matrix metallopeptidase 25

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of MMP25 mRNA

NCBI chr10:12,661,297...12,676,119
Ensembl chr10:12,661,208...12,675,871

G

mercaptopyruvate sulfurtransferase

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of MPST mRNA

NCBI chr 7:109,955,581...109,963,155
Ensembl chr 7:109,955,675...109,963,141

G

MRN complex interacting protein

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of MRNIP mRNA

NCBI chr10:34,501,359...34,525,474
Ensembl chr10:34,501,384...34,525,469

G

mitochondrial ribosomal protein L11

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of MRPL11 mRNA

NCBI chr 1:202,264,419...202,267,288
Ensembl chr 1:202,264,471...202,267,756

G

mitochondrial ribosomal protein L39

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of MRPL39 mRNA

NCBI chr11:23,779,655...23,795,146
Ensembl chr11:23,779,662...23,795,125

G

mitochondrial ribosomal protein L45

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of MRPL45 mRNA

NCBI chr10:82,308,650...82,320,474
Ensembl chr10:82,308,427...82,320,474

G

mitochondrial ribosomal protein L53

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of MRPL53 mRNA

NCBI chr 4:115,615,329...115,616,219

G

mitochondrial ribosomal protein S12

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of MRPS12 mRNA

NCBI chr 1:84,025,896...84,028,896
Ensembl chr 1:84,025,899...84,028,780

G

mitochondrial ribosomal protein S18A

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of MRPS18A mRNA

NCBI chr 9:14,853,322...14,869,819
Ensembl chr 9:14,853,291...14,869,835

G

mitochondrial ribosomal protein S24

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of MRPS24 mRNA

NCBI chr14:80,584,671...80,588,801
Ensembl chr14:80,584,673...80,588,871

G

mitochondrial ribosomal protein S5

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of MRPS5 mRNA

NCBI chr 3:114,821,046...114,837,291
Ensembl chr 3:114,821,046...114,837,291

G

mitochondrial ribosome recycling factor

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of MRRF mRNA

NCBI chr 3:19,487,124...19,543,911
Ensembl chr 3:19,487,182...19,543,908

G

metastasis associated 1 family, member 3

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of MTA3 mRNA

NCBI chr 6:10,867,028...10,987,221
Ensembl chr 6:10,867,011...10,986,883

G

myotubularin related protein 4

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of MTMR4 mRNA

NCBI chr10:72,393,411...72,416,342
Ensembl chr10:72,392,551...72,416,342

G

mucin 1, cell surface associated

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of MUC1 mRNA

NCBI chr 2:174,635,989...174,640,738
Ensembl chr 2:174,635,995...174,640,733

G

MYB proto-oncogene like 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of MYBL2 mRNA

NCBI chr 3:151,705,254...151,733,714
Ensembl chr 3:151,705,288...151,733,708

G

MYC binding protein 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of MYCBP2 mRNA

NCBI chr15:79,937,354...80,175,432
Ensembl chr15:79,937,354...80,175,498

G

myosin heavy chain 7

multiple interactions

Hydralazine inhibits the reaction [Nitric Oxide deficiency results in increased expression of MYH7 mRNA]

NCBI chr15:28,446,550...28,469,888
Ensembl chr15:28,446,550...28,468,217

G

myosin light chain 6B

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of MYL6B mRNA

NCBI chr X:40,572,012...40,572,991

G

myomesin 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of MYOM1 mRNA

NCBI chr 9:110,916,156...111,039,344
Ensembl chr 9:110,915,943...111,039,344

G

myotilin

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of MYOT mRNA

NCBI chr18:36,705,244...36,724,849
Ensembl chr18:36,705,314...36,724,841

G

N(alpha)-acetyltransferase 10, NatA catalytic subunit

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of NAA10 mRNA

NCBI chr X:151,656,056...151,661,304
Ensembl chr X:151,656,056...151,661,252

G

N(alpha)-acetyltransferase 38, NatC auxiliary subunit

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of NAA38 mRNA

NCBI chr10:54,117,754...54,118,913
Ensembl chr10:54,117,163...54,119,494

G

sodium leak channel, non-selective

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of NALCN mRNA

NCBI chr15:100,398,583...100,741,243
Ensembl chr15:100,398,615...100,741,001

G

NALCN channel auxiliary factor 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of NALF2 mRNA

NCBI chr X:64,925,100...64,951,074
Ensembl chr X:64,925,051...64,951,077

G

nicotinamide phosphoribosyltransferase

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in decreased expression of NAMPT mRNA

NCBI chr 6:49,425,316...49,462,109
Ensembl chr 6:49,424,332...49,462,100

G

nucleosome assembly protein 1-like 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of NAP1L1 mRNA

NCBI chr 7:46,933,278...46,957,853
Ensembl chr 7:46,933,356...46,956,593

G

N-acetyltransferase 2

increases acetylation
affects metabolic processing

NAT2 protein results in increased acetylation of Hydralazine
NAT2 protein affects the metabolism of Hydralazine

NCBI chr16:22,207,362...22,238,513
Ensembl chr16:22,208,194...22,238,520

G

neurobeachin-like 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of NBEAL1 mRNA

NCBI chr 9:61,575,154...61,743,896
Ensembl chr 9:61,575,356...61,736,750

G

NBR1, autophagy cargo receptor

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in decreased expression of NBR1 mRNA

NCBI chr10:86,477,775...86,506,418
Ensembl chr10:86,478,290...86,506,412

G

neutrophil cytosolic factor 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of NCF1 mRNA

NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646

G

nuclear receptor coactivator 4

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of NCOA4 mRNA

NCBI chr16:7,389,222...7,409,564
Ensembl chr16:7,366,542...7,409,641
Ensembl chr16:7,366,542...7,409,641

G

nuclear receptor co-repressor 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of NCOR1 mRNA

NCBI chr10:46,999,536...47,142,294
Ensembl chr10:46,999,536...47,141,032

G

natural cytotoxicity triggering receptor 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in decreased expression of NCR1 mRNA

NCBI chr 1:69,614,744...69,622,594
Ensembl chr 1:69,616,601...69,660,558

G

NADH:ubiquinone oxidoreductase subunit A1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of NDUFA1 mRNA

NCBI chr X:116,424,223...116,427,875
Ensembl chr X:116,424,223...116,428,633

G

NADH:ubiquinone oxidoreductase subunit A13

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of NDUFA13 mRNA

NCBI chr16:19,526,633...19,533,567
Ensembl chr16:19,526,565...19,535,726
Ensembl chr 7:19,526,565...19,535,726

G

NADH:ubiquinone oxidoreductase subunit A3

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of NDUFA3 mRNA

NCBI chr 1:65,597,567...65,600,197
Ensembl chr 1:65,597,578...65,600,235

G

NADH:ubiquinone oxidoreductase subunit A5

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of NDUFA5 mRNA

NCBI chr 4:52,997,327...53,005,685
Ensembl chr 4:52,995,546...53,005,598
Ensembl chr 5:52,995,546...53,005,598

G

NADH:ubiquinone oxidoreductase subunit A6

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of NDUFA6 mRNA

NCBI chr 7:113,866,382...113,870,239
Ensembl chr 7:113,866,382...113,870,239

G

NADH:ubiquinone oxidoreductase complex assembly factor 6

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of NDUFAF6 mRNA

NCBI chr 5:24,147,712...24,171,981
Ensembl chr 5:24,147,735...24,171,951

G

NADH:ubiquinone oxidoreductase subunit B1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of NDUFB1 mRNA

NCBI chr 6:121,115,649...121,124,055

G

NADH:ubiquinone oxidoreductase subunit B10

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of NDUFB10 mRNA

NCBI chr10:13,749,273...13,751,434
Ensembl chr10:13,749,275...13,751,442

G

NADH:ubiquinone oxidoreductase subunit B2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of NDUFB2 mRNA

NCBI chr 4:68,367,526...68,374,609
Ensembl chr15:46,536,062...46,536,851
Ensembl chr 4:46,536,062...46,536,851

G

NADH:ubiquinone oxidoreductase subunit S5

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of NDUFS5 mRNA

NCBI chr 5:135,974,029...135,979,705
Ensembl chr 5:135,974,034...135,979,603
Ensembl chr14:135,974,034...135,979,603
Ensembl chr 2:135,974,034...135,979,603

G

NEDD1 gamma-tubulin ring complex targeting factor

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of NEDD1 mRNA

NCBI chr 7:27,233,050...27,274,486
Ensembl chr 7:27,233,316...27,274,486

G

neuroepithelial cell transforming 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in decreased expression of NET1 mRNA

NCBI chr17:66,341,251...66,370,445
Ensembl chr17:66,340,728...66,370,441

G

neurofibromin 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of NF1 mRNA

NCBI chr10:64,306,027...64,539,112
Ensembl chr10:64,306,301...64,536,658

G

nuclear factor of activated T-cells 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of NFATC2 mRNA

NCBI chr 3:157,195,970...157,328,640
Ensembl chr 3:157,198,872...157,328,325

G

NHL repeat containing 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in decreased expression of NHLRC2 mRNA

NCBI chr 1:255,589,743...255,648,904
Ensembl chr 1:255,589,742...255,651,408

G

NHS actin remodeling regulator

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of NHS mRNA

NCBI chr X:32,553,300...32,892,961
Ensembl chr X:32,552,026...32,889,992

G

NMD3 ribosome export adaptor

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of NMD3 mRNA

NCBI chr 2:154,012,973...154,038,466
Ensembl chr 2:154,013,020...154,039,259

G

NME/NM23 nucleoside diphosphate kinase 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of NME1 mRNA

NCBI chr10:78,907,036...78,929,659
Ensembl chr10:78,906,083...78,916,408

G

nucleotide-binding oligomerization domain containing 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of NOD1 mRNA

NCBI chr 4:84,060,871...84,111,668
Ensembl chr 4:84,060,880...84,111,404

G

nitric oxide synthase 1

increases expression

Hydralazine results in increased expression of NOS1 mRNA

NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945

G

NOVA alternative splicing regulator 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of NOVA1 mRNA

NCBI chr 6:63,780,105...63,905,567
Ensembl chr 6:63,783,489...63,906,289

G

neuronal PAS domain protein 3

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of NPAS3 mRNA

NCBI chr 6:70,702,773...71,527,928
Ensembl chr 6:70,703,170...71,524,884

G

neural proliferation, differentiation and control, 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of NPDC1 mRNA

NCBI chr 3:8,220,446...8,226,446
Ensembl chr 3:8,213,663...8,226,866

G

nephrocystin 4

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of NPHP4 mRNA

NCBI chr 5:162,986,157...163,073,708
Ensembl chr 5:162,988,370...163,073,706

G

natriuretic peptide B

multiple interactions

Hydralazine inhibits the reaction [Nitric Oxide deficiency results in increased expression of NPPB mRNA]

NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168

G

natriuretic peptide receptor 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of NPR1 mRNA

NCBI chr 2:175,934,181...175,950,118
Ensembl chr 2:175,934,181...175,949,505

G

nuclear receptor subfamily 1, group H, member 3

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of NR1H3 mRNA

NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722

G

nuclear receptor subfamily 2, group C, member 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of NR2C2 mRNA

NCBI chr 4:124,610,216...124,666,813
Ensembl chr 4:124,608,960...124,661,902

G

nuclear receptor subfamily 3, group C, member 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of NR3C1 mRNA

NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375

G

neuronal regeneration related protein

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of NREP mRNA

NCBI chr18:25,017,069...25,046,593
Ensembl chr18:25,017,083...25,046,591

G

neurexin 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of NRXN2 mRNA

NCBI chr 1:203,726,420...203,842,301
Ensembl chr 1:203,735,753...203,842,297

G

NAD(P) dependent steroid dehydrogenase-like

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of NSDHL mRNA

NCBI chr X:150,775,034...150,807,161
Ensembl chr X:150,775,080...150,807,142

G

NSFL1 cofactor

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of NSFL1C mRNA

NCBI chr 3:139,978,306...140,002,876
Ensembl chr 3:139,978,301...140,002,870

G

NOP2/Sun RNA methyltransferase 4

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of NSUN4 mRNA

NCBI chr 5:129,511,224...129,532,498
Ensembl chr 5:129,512,307...129,532,423
Ensembl chr 5:129,512,307...129,532,423

G

N-terminal asparagine amidase

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of NTAN1 mRNA

NCBI chr10:2,111,090...2,126,119

G

neurotensin receptor 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in decreased expression of NTSR2 mRNA

NCBI chr 6:39,424,297...39,431,015
Ensembl chr 6:39,424,324...39,431,014

G

nuclear distribution C, dynein complex regulator

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of NUDC mRNA

NCBI chr 5:145,758,006...145,771,390
Ensembl chr 5:145,758,002...145,771,425

G

nudix hydrolase 7

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in decreased expression of NUDT7 mRNA

NCBI chr19:42,125,679...42,151,198
Ensembl chr19:42,125,711...42,151,081

G

NUMB, endocytic adaptor protein

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of NUMB mRNA

NCBI chr 6:103,431,400...103,553,422
Ensembl chr 6:103,431,400...103,553,354

G

nucleoporin 153

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of NUP153 mRNA

NCBI chr17:17,972,217...18,024,876
Ensembl chr17:17,972,217...18,024,876

G

nuclear protein 1, transcriptional regulator

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of NUPR1 mRNA

NCBI chr 1:181,213,292...181,215,327
Ensembl chr 1:181,213,368...181,215,281

G

neurexophilin 3

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of NXPH3 mRNA

NCBI chr10:80,456,283...80,459,949
Ensembl chr10:80,455,429...80,462,415

G

ornithine decarboxylase antizyme 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of OAZ1 mRNA

NCBI chr 7:8,883,855...8,886,315
Ensembl chr 7:8,883,851...8,886,310

G

obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of OBSCN mRNA

NCBI chr10:43,774,113...43,919,718
Ensembl chr10:43,789,293...43,919,723

G

OCIA domain containing 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of OCIAD2 mRNA

NCBI chr14:34,873,668...34,889,276
Ensembl chr14:34,873,820...34,889,265

G

orofacial cleft 1 candidate 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in decreased expression of OFCC1 mRNA

NCBI chr17:24,506,919...24,813,225
Ensembl chr17:24,539,047...24,811,079

G

O-GlcNAcase

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of OGA mRNA

NCBI chr 1:244,598,285...244,633,835
Ensembl chr 1:244,598,292...244,634,359

G

8-oxoguanine DNA glycosylase

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of OGG1 mRNA

NCBI chr 4:146,474,701...146,481,959
Ensembl chr 4:146,474,750...146,484,766

G

O-linked N-acetylglucosamine (GlcNAc) transferase

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of OGT mRNA

NCBI chr X:66,771,278...66,816,148
Ensembl chr X:66,771,349...66,816,146

G

OPA1, mitochondrial dynamin like GTPase

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of OPA1 mRNA

NCBI chr11:71,108,100...71,185,170
Ensembl chr11:71,109,873...71,185,109

G

opioid receptor, delta 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in decreased expression of OPRD1 mRNA

NCBI chr 5:144,306,188...144,340,960
Ensembl chr 5:144,306,188...144,340,960

G

olfactory receptor family 9 subfamily I member 1B

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of OR9I1 mRNA

NCBI chr 1:211,096,191...211,097,141
Ensembl chr 1:211,090,402...211,097,815

G

purinergic receptor P2X 3

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of P2RX3 mRNA

NCBI chr 3:70,080,850...70,124,664
Ensembl chr 3:70,080,851...70,125,178

G

poly(A) binding protein cytoplasmic 1 like 2B

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PABPC1L2B mRNA

G

platelet-activating factor acetylhydrolase 1b, catalytic subunit 3

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PAFAH1B3 mRNA

NCBI chr 1:80,881,263...80,883,789
Ensembl chr 1:80,881,309...80,883,893

G

Parkinsonism associated deglycase

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PARK7 mRNA

NCBI chr 5:161,353,718...161,376,993
Ensembl chr 5:161,353,719...161,376,970

G

poly (ADP-ribose) polymerase 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PARP1 mRNA

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

poly (ADP-ribose) polymerase family, member 14

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PARP14 mRNA

NCBI chr11:64,902,848...64,934,916
Ensembl chr11:64,902,785...64,934,916

G

PAS domain containing repressor 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PASD1 mRNA

NCBI chr X:149,617,933...149,639,214
Ensembl chr X:149,620,972...149,638,675

G

PBX homeobox 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PBX2 mRNA

NCBI chr20:4,151,500...4,156,425
Ensembl chr20:4,151,500...4,156,425

G

pterin-4 alpha-carbinolamine dehydratase 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PCBD1 mRNA

NCBI chr20:29,037,545...29,044,322
Ensembl chr20:28,953,864...29,044,292
Ensembl chr20:28,953,864...29,044,292

G

propionyl-CoA carboxylase subunit beta

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PCCB mRNA

NCBI chr 8:101,591,218...101,641,213
Ensembl chr 8:101,590,737...101,641,234

G

protocadherin related 15

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PCDH15 mRNA

NCBI chr20:13,997,094...15,496,446
Ensembl chr20:13,963,565...15,494,719

G

proliferating cell nuclear antigen

multiple interactions

[troglitazone co-treated with [Hydrochlorothiazide co-treated with Hydralazine co-treated with Reserpine]] results in decreased expression of PCNA protein

NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995

G

platelet derived growth factor receptor beta

decreases expression

hydralazine decreases expression of Pdgfrb protein in liver

RGD

NCBI chr18:54,499,962...54,538,840
Ensembl chr18:54,499,964...54,538,843

G

phosphatidylethanolamine binding protein 4

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PEBP4 mRNA

NCBI chr15:44,920,946...45,134,188
Ensembl chr15:44,921,886...45,134,191

G

6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PFKFB4 mRNA

NCBI chr 8:109,643,558...109,687,006
Ensembl chr 8:109,643,937...109,685,634

G

profilin 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PFN1 mRNA

NCBI chr10:55,365,263...55,367,968
Ensembl chr10:55,365,262...55,527,631

G

phosphoglycerate mutase 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PGAM2 mRNA

NCBI chr14:80,681,796...80,683,907
Ensembl chr14:80,681,776...80,683,940

G

phosphoglucomutase 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PGM1 mRNA

NCBI chr 5:114,595,298...114,654,728
Ensembl chr 5:114,595,293...114,654,728

G

prohibitin 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PHB1 mRNA

NCBI chr10:80,605,268...80,618,043
Ensembl chr10:80,605,251...80,618,042

G

polyhomeotic homolog 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in decreased expression of PHC1 mRNA

NCBI chr 4:155,510,274...155,532,636
Ensembl chr 4:155,510,274...155,533,959

G

polyhomeotic homolog 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PHC2 mRNA

NCBI chr 5:141,000,604...141,099,268
Ensembl chr 5:141,050,842...141,099,268

G

PHD finger protein 24

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PHF24 mRNA

NCBI chr 5:57,143,428...57,171,054
Ensembl chr 5:57,142,632...57,168,497

G

phosphatidylinositol glycan anchor biosynthesis, class S

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PIGS mRNA

NCBI chr10:63,222,611...63,237,190
Ensembl chr10:63,222,572...63,237,187

G

prolactin induced protein

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PIP mRNA

NCBI chr 4:70,787,627...70,791,921
Ensembl chr 4:70,787,627...70,791,921

G

phospholipase C, gamma 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PLCG1 mRNA

NCBI chr 3:149,385,587...149,416,330
Ensembl chr 3:149,385,587...149,416,330

G

pleiotropic regulator 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PLRG1 mRNA

NCBI chr 2:168,408,139...168,424,470
Ensembl chr 2:168,408,124...168,424,522

G

plexin domain containing 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PLXDC1 mRNA

NCBI chr10:82,922,499...82,982,124
Ensembl chr10:82,922,508...82,982,130

G

phosphomannomutase 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PMM2 mRNA

NCBI chr10:6,961,521...6,982,913
Ensembl chr10:6,961,709...6,983,098

G

phosphomevalonate kinase

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PMVK mRNA

NCBI chr 2:174,876,586...174,886,365
Ensembl chr 2:174,876,657...174,886,364

G

DNA polymerase epsilon 4, accessory subunit

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of POLE4 mRNA

NCBI chr 4:115,165,285...115,171,097
Ensembl chr 4:115,165,285...115,171,097

G

RNA polymerase I subunit H, antisense

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of POLR1HASP mRNA

NCBI chr 9:16,098,624...16,099,790
Ensembl chr 9:16,098,624...16,099,790

G

RNA polymerase II, I and III subunit L

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of POLR2L mRNA

NCBI chr 1:196,570,051...196,572,060
Ensembl chr19:8,335,702...8,335,905

G

POP5 homolog, ribonuclease P/MRP subunit

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of POP5 mRNA

NCBI chr12:41,376,755...41,384,882
Ensembl chr12:41,376,755...41,381,336

G

peptidylprolyl isomerase like 4

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PPIL4 mRNA

NCBI chr 1:2,273,582...2,305,639
Ensembl chr 1:2,273,609...2,305,632

G

protein phosphatase 1, regulatory subunit 12A

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PPP1R12A mRNA

NCBI chr 7:43,482,808...43,593,689
Ensembl chr 7:43,482,803...43,593,425

G

protein phosphatase 1, regulatory subunit 9A

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PPP1R9A mRNA

NCBI chr 4:32,970,501...33,292,360
Ensembl chr 4:33,024,450...33,286,907

G

protein phosphatase 2 scaffold subunit A beta

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PPP2R1B mRNA

NCBI chr 8:51,195,860...51,228,442
Ensembl chr 8:51,186,717...51,228,485

G

proline-rich protein BstNI subfamily 3

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PRB3 mRNA

NCBI chr 4:165,564,424...165,569,229
Ensembl chr 4:165,564,424...165,569,227

G

PRKCSH beta subunit of glucosidase II

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PRKCSH mRNA

NCBI chr 8:20,534,787...20,546,493
Ensembl chr 8:20,534,880...20,546,492

G

protein kinase cGMP-dependent 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PRKG1 mRNA

NCBI chr 1:228,409,605...229,638,794
Ensembl chr 1:228,408,947...229,639,080

G

prominin 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PROM2 mRNA

NCBI chr 3:114,747,654...114,761,787
Ensembl chr 3:114,747,654...114,761,787

G

pre-mRNA processing factor 18

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PRPF18 mRNA

NCBI chr17:73,630,560...73,661,210
Ensembl chr17:73,630,571...73,690,979

G

proline rich 13

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PRR13 mRNA

NCBI chr 7:133,592,511...133,595,817
Ensembl chr 7:133,592,490...133,601,005

G

phosphoribosyl transferase domain containing 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PRTFDC1 mRNA

NCBI chr17:83,549,608...83,654,517
Ensembl chr17:83,548,803...83,655,179

G

pleckstrin and Sec7 domain containing 3

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PSD3 mRNA

NCBI chr16:21,465,643...22,035,846
Ensembl chr16:21,465,639...22,034,547

G

proteasome 20S subunit alpha 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PSMA2 mRNA

NCBI chr17:50,554,536...50,564,923
Ensembl chr17:50,551,924...50,564,938

G

proteasome 20S subunit alpha 4

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PSMA4 mRNA

NCBI chr 8:55,340,431...55,347,893
Ensembl chr 8:55,340,386...55,347,890

G

proteasome 20S subunit beta 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PSMB1 mRNA

NCBI chr 1:56,442,432...56,463,544
Ensembl chr 1:56,420,618...56,463,560

G

proteasome 20S subunit beta 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PSMB2 mRNA

NCBI chr 5:138,970,564...139,002,715
Ensembl chr 5:138,970,533...139,021,137

G

proteasome 20S subunit beta 3

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PSMB3 mRNA

NCBI chr10:82,697,425...82,704,521
Ensembl chr10:82,697,425...82,704,521

G

proteasome 20S subunit beta 6

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PSMB6 mRNA

NCBI chr10:55,239,256...55,241,586
Ensembl chr10:55,239,241...55,241,586

G

proteasome 20S subunit beta 9

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PSMB9 mRNA

NCBI chr20:4,667,044...4,672,512
Ensembl chr20:4,666,046...4,672,512

G

proteasome 26S subunit, ATPase 6

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PSMC6 mRNA

NCBI chr15:18,542,585...18,564,057
Ensembl chr15:18,542,563...18,564,055

G

proteasome 26S subunit, non-ATPase 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PSMD1 mRNA

NCBI chr 9:86,709,714...86,785,213
Ensembl chr 9:86,709,947...86,785,211

G

proteasome 26S subunit, non-ATPase 3

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in decreased expression of PSMD3 mRNA

NCBI chr10:83,643,473...83,655,620
Ensembl chr10:83,643,647...83,655,618

G

proteasome 26S subunit ubiquitin receptor, non-ATPase 4

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PSMD4 mRNA

NCBI chr 2:182,598,934...182,608,250
Ensembl chr 2:182,598,934...182,608,194

G

proteasome 26S subunit, non-ATPase 8

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PSMD8 mRNA

NCBI chr 1:84,474,377...84,481,209
Ensembl chr 1:84,474,378...84,481,209

G

proteasome assembly chaperone 3

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PSMG3 mRNA

NCBI chr12:14,809,440...14,812,357
Ensembl chr12:14,809,450...14,812,342

G

protein tyrosine kinase 2 beta

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PTK2B mRNA

NCBI chr15:40,360,722...40,481,235
Ensembl chr15:40,360,723...40,481,282

G

prothymosin alpha

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PTMA mRNA

NCBI chr 9:87,176,251...87,180,333
Ensembl chr 9:87,176,230...87,180,333

G

protein tyrosine phosphatase, receptor type, J

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PTPRJ mRNA

NCBI chr 3:76,405,917...76,561,842
Ensembl chr 3:76,405,927...76,562,260

G

poly-U binding splicing factor 60

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PUF60 mRNA

NCBI chr 7:107,782,799...107,793,759
Ensembl chr 7:107,782,770...107,794,531

G

pumilio RNA-binding family member 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PUM1 mRNA

NCBI chr 5:142,836,933...142,954,331
Ensembl chr 5:142,837,127...142,954,039

G

PYD and CARD domain containing

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PYCARD mRNA

NCBI chr 1:182,601,657...182,603,013
Ensembl chr 1:182,601,174...182,602,955

G

pyrroline-5-carboxylate reductase 3

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of PYCR3 mRNA

NCBI chr 7:107,603,543...107,608,831
Ensembl chr 7:107,581,930...107,608,799

G

RAB13, member RAS oncogene family

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RAB13 mRNA

NCBI chr 2:175,674,894...175,680,043
Ensembl chr 2:175,675,005...175,680,036

G

RAB1A, member RAS oncogene family

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RAB1A mRNA

NCBI chr14:94,422,219...94,448,799
Ensembl chr14:94,415,275...94,448,248

G

RAB30, member RAS oncogene family

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RAB30 mRNA

NCBI chr 1:146,803,719...146,898,369
Ensembl chr 1:146,803,714...146,892,181

G

RAB3A, member RAS oncogene family

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RAB3A mRNA

NCBI chr16:18,684,185...18,688,297
Ensembl chr16:18,684,188...18,688,336

G

RAB3D, member RAS oncogene family

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RAB3D mRNA

NCBI chr 8:20,438,622...20,449,269
Ensembl chr 8:20,439,294...20,449,185

G

RAB6A, member RAS oncogene family

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RAB6A mRNA

NCBI chr 1:154,957,870...155,008,922
Ensembl chr 1:154,958,189...154,996,715

G

rabaptin, RAB GTPase binding effector protein 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RABEP2 mRNA

NCBI chr 1:181,010,305...181,026,651
Ensembl chr 1:181,010,305...181,026,648

G

RAB guanine nucleotide exchange factor 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RABGEF1 mRNA

NCBI chr12:26,459,190...26,503,790
Ensembl chr12:26,460,175...26,503,744

G

RAD21 cohesin complex component

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RAD21 mRNA

NCBI chr 7:83,287,867...83,314,810
Ensembl chr 7:83,287,870...83,314,817

G

ral guanine nucleotide dissociation stimulator

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RALGDS mRNA

NCBI chr 3:11,839,686...11,880,059
Ensembl chr 3:11,839,416...11,880,059

G

Ral GEF with PH domain and SH3 binding motif 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RALGPS1 mRNA

NCBI chr 3:16,433,323...16,670,276
Ensembl chr 3:16,433,742...16,669,972

G

receptor activity modifying protein 2

multiple interactions

Hydralazine inhibits the reaction [Nitric Oxide deficiency results in increased expression of RAMP2 protein]

NCBI chr10:86,187,366...86,190,692
Ensembl chr10:86,188,812...86,231,829

G

receptor activity modifying protein 3

multiple interactions

Hydralazine inhibits the reaction [Nitric Oxide deficiency results in increased expression of RAMP3 protein]

NCBI chr14:81,527,404...81,544,905
Ensembl chr14:81,527,385...81,544,902

G

RAP1A, member of RAS oncogene family

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RAP1A mRNA

NCBI chr 2:193,208,631...193,286,513
Ensembl chr 2:193,208,635...193,286,501

G

retinoic acid receptor, beta

decreases methylation

Hydralazine results in decreased methylation of RARB promoter

NCBI chr15:8,700,533...9,051,288
Ensembl chr15:8,406,492...9,051,288

G

RB transcriptional corepressor like 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RBL1 mRNA

NCBI chr 3:145,806,160...145,869,434
Ensembl chr 3:145,807,095...145,869,330

G

RNA binding motif protein 22

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RBM22 mRNA

NCBI chr18:54,013,374...54,024,182
Ensembl chr18:54,013,351...54,024,569

G

RNA binding motif protein 4

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RBM4 mRNA

NCBI chr 1:202,078,442...202,087,506
Ensembl chr 1:202,085,279...202,105,380

G

RNA terminal phosphate cyclase-like 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RCL1 mRNA

NCBI chr 1:226,824,561...226,869,046
Ensembl chr 1:226,824,534...226,902,315

G

receptor accessory protein 4

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of REEP4 mRNA

NCBI chr15:45,620,317...45,623,524
Ensembl chr15:45,619,941...45,623,526

G

regenerating family member 1 alpha

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in decreased expression of REG1A mRNA

NCBI chr 4:110,892,451...110,895,115
Ensembl chr 4:110,892,453...110,895,570

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

Hydralazine inhibits the reaction [Acrolein promotes the reaction [RELA protein binds to FASLG promoter]]; Hydralazine inhibits the reaction [Acrolein promotes the reaction [Zidovudine promotes the reaction [RELA protein binds to FASLG promoter]]]; Hydralazine inhibits the reaction [Zidovudine promotes the reaction [Acrolein promotes the reaction [RELA protein binds to FASLG promoter]]]; Hydralazine inhibits the reaction [Zidovudine promotes the reaction [RELA protein binds to FASLG promoter]]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

renin

multiple interactions
increases activity
increases expression

Alprenolol inhibits the reaction [Hydralazine results in increased expression of REN protein]
Hydralazine results in increased activity of REN protein

PMID:231700 PMID:923630 PMID:2203898 PMID:2953239 PMID:3154321

NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489

G

retention in endoplasmic reticulum sorting receptor 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RER1 mRNA

NCBI chr 5:165,634,567...165,646,643
Ensembl chr 5:165,634,300...165,646,750

G

regulatory factor X1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RFX1 mRNA

NCBI chr19:24,061,336...24,092,044
Ensembl chr19:24,061,336...24,092,044

G

regulator of G-protein signaling 7 binding protein

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RGS7BP mRNA

NCBI chr 2:36,133,944...36,231,505
Ensembl chr 2:36,139,201...36,231,505

G

regulator of G-protein signaling 9

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RGS9 mRNA

NCBI chr10:94,195,265...94,270,892
Ensembl chr10:94,197,054...94,270,892

G

regulator of G protein signaling 9 binding protein

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RGS9BP mRNA

NCBI chr 1:88,249,438...88,250,151
Ensembl chr 1:88,249,438...88,250,151

G

Ras and Rab interactor 3

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RIN3 mRNA

NCBI chr 6:121,431,776...121,540,956
Ensembl chr 6:121,431,339...121,540,957

G

Ras and Rab interactor-like

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RINL mRNA

NCBI chr 1:84,077,011...84,088,590
Ensembl chr 1:84,077,265...84,088,330

G

receptor interacting serine/threonine kinase 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RIPK1 mRNA

NCBI chr17:30,839,639...30,871,824
Ensembl chr17:30,839,650...30,871,824

G

ripply transcriptional repressor 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RIPPLY1 mRNA

NCBI chr X:103,436,731...103,440,904
Ensembl chr X:103,436,729...103,443,349

G

required for meiotic nuclear division 5 homolog B

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RMND5B mRNA

NCBI chr10:35,881,250...35,892,322
Ensembl chr10:35,881,268...35,892,265

G

ring finger protein 152

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RNF152 mRNA

NCBI chr13:21,324,039...21,403,405
Ensembl chr13:21,323,824...21,403,113

G

ring finger protein 187

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RNF187 mRNA

NCBI chr10:43,709,493...43,715,392
Ensembl chr10:43,702,357...43,716,157

G

roundabout guidance receptor 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ROBO2 mRNA

NCBI chr11:12,528,949...14,096,726
Ensembl chr11:12,528,951...13,041,536

G

reactive oxygen species modulator 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ROMO1 mRNA

NCBI chr 3:144,659,709...144,661,310
Ensembl chr 3:144,659,826...144,661,310

G

ribosomal protein L10A

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL10A mRNA

NCBI chr20:6,388,800...6,391,358
Ensembl chr20:6,385,823...6,391,357
Ensembl chr 9:6,385,823...6,391,357

G

ribosomal protein L13

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL13 mRNA

NCBI chr19:51,153,990...51,156,541
Ensembl chr19:51,153,924...51,163,014

G

ribosomal protein L17

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL17 mRNA

NCBI chr18:68,581,141...68,584,253
Ensembl chr18:68,581,098...68,584,253
Ensembl chr 3:68,581,098...68,584,253

G

ribosomal protein L18A

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL18A mRNA

NCBI chr16:18,542,555...18,544,578
Ensembl chr16:18,542,566...18,545,546
Ensembl chr 1:18,542,566...18,545,546

G

ribosomal protein L23A

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL23A mRNA

NCBI chr10:63,076,660...63,079,346
Ensembl chr10:63,076,066...63,079,346
Ensembl chr15:63,076,066...63,079,346

G

ribosomal protein L24

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL24 mRNA

NCBI chr11:44,653,937...44,659,346
Ensembl chr11:44,653,937...44,659,370

G

ribosomal protein L26

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL26 mRNA

NCBI chr10:53,610,836...53,613,966
Ensembl chr10:53,610,421...53,613,966

G

ribosomal protein L27

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL27 mRNA

NCBI chr10:86,375,511...86,379,210
Ensembl chr10:86,375,454...86,379,193

G

ribosomal protein L31

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL31 mRNA

NCBI chr 9:41,647,397...41,651,441
Ensembl chr 9:41,647,426...41,662,129
Ensembl chr 8:41,647,426...41,662,129

G

ribosomal protein L34

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL34 mRNA

NCBI chr 2:219,284,373...219,288,108
Ensembl chr 2:219,284,382...219,288,111
Ensembl chr17:219,284,382...219,288,111

G

ribosomal protein L36

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL36 mRNA

NCBI chr 9:1,441,986...1,447,397
Ensembl chr 6:98,809,534...98,809,897
Ensembl chr 5:98,809,534...98,809,897

G

ribosomal protein L37A

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL37A mRNA

NCBI chr 9:74,298,843...74,300,926

G

ribosomal protein L39

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL39 mRNA

NCBI chr  X:116,327,216...116,330,211
Ensembl chr18:6,326,330...6,326,692
Ensembl chr  X:6,326,330...6,326,692
Ensembl chr  X:6,326,330...6,326,692
Ensembl chr15:6,326,330...6,326,692
Ensembl chr20:6,326,330...6,326,692
Ensembl chr 7:6,326,330...6,326,692

G

ribosomal protein L41

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL41 mRNA

NCBI chr 7:977,885...978,965

G

ribosomal protein L7

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPL7 mRNA

NCBI chr 5:3,217,184...3,220,192

G

ribosomal protein lateral stalk subunit P1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPLP1 mRNA

NCBI chr 8:62,394,008...62,395,341
Ensembl chr 8:62,393,177...62,395,339

G

ribonuclease P/MRP subunit p21

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPP21 mRNA

NCBI chr20:2,018,170...2,020,100
Ensembl chr20:2,018,147...2,020,106

G

ribosomal protein S11

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPS11 mRNA

NCBI chr 1:95,605,690...95,607,798
Ensembl chr 1:95,605,692...95,607,874

G

ribosomal protein S12

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPS12 mRNA

NCBI chr 1:21,680,854...21,683,010
Ensembl chr 1:21,680,852...21,683,014

G

ribosomal protein S19 binding protein 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPS19BP1 mRNA

NCBI chr 7:111,809,354...111,812,741
Ensembl chr 7:111,809,355...111,812,757

G

ribosomal protein S2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPS2 mRNA

NCBI chr10:13,747,316...13,749,165
Ensembl chr10:13,747,301...13,749,163

G

ribosomal protein S27

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPS27 mRNA

NCBI chr 2:175,665,858...175,666,963
Ensembl chr 2:175,665,853...175,666,964
Ensembl chr12:175,665,853...175,666,964

G

ribosomal protein S27a

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPS27A mRNA

NCBI chr14:103,285,734...103,288,011
Ensembl chr14:103,285,734...103,288,011
Ensembl chr 5:103,285,734...103,288,011
Ensembl chr 5:103,285,734...103,288,011

G

ribosomal protein S6 kinase A5

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPS6KA5 mRNA

NCBI chr 6:119,828,823...120,006,190
Ensembl chr 6:119,828,846...120,006,224

G

ribosomal protein S9

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RPS9 mRNA

NCBI chr 1:65,511,723...65,515,076
Ensembl chr 1:65,511,723...65,515,123

G

R-spondin 4

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RSPO4 mRNA

NCBI chr 3:140,357,256...140,391,780
Ensembl chr 3:140,357,424...140,388,254

G

arginine and serine rich protein 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RSRP1 mRNA

NCBI chr 5:147,147,774...147,151,523
Ensembl chr 5:147,147,784...147,151,523

G

RT1 class I, locus CE16

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of HLA-A mRNA

NCBI chr20:3,257,109...3,260,747
Ensembl chr20:3,257,123...3,279,563

G

RT1 class II, locus DOb

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of HLA-DOB mRNA

NCBI chr20:4,619,418...4,625,627
Ensembl chr20:4,619,816...4,625,667

G

reticulon 4 receptor-like 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RTN4RL1 mRNA

NCBI chr10:60,043,246...60,116,977
Ensembl chr10:60,043,002...60,116,978

G

RWD domain containing 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RWDD1 mRNA

NCBI chr20:25,949,723...25,967,147
Ensembl chr20:25,941,966...25,967,193

G

retinoid X receptor gamma

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of RXRG mRNA

NCBI chr13:79,743,430...79,785,173
Ensembl chr13:79,743,563...79,785,167

G

S100 calcium binding protein A6

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of S100A6 mRNA

NCBI chr 2:176,100,619...176,102,181
Ensembl chr 2:176,100,899...176,102,180

G

S100 calcium binding protein A8

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in decreased expression of S100A8 mRNA

NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643

G

S100P binding protein

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of S100PBP mRNA

NCBI chr 5:141,494,352...141,535,752
Ensembl chr 5:141,494,353...141,535,525

G

sterile alpha motif domain containing 4A

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SAMD4A mRNA

NCBI chr15:20,135,994...20,352,131
Ensembl chr15:20,134,377...20,348,380

G

SAMM50 sorting and assembly machinery component

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SAMM50 mRNA

NCBI chr 7:115,317,472...115,341,682
Ensembl chr 7:115,317,404...115,341,682

G

store-operated calcium entry-associated regulatory factor

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SARAF mRNA

NCBI chr16:58,017,231...58,035,481
Ensembl chr16:58,017,231...58,035,545

G

SREBF chaperone

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SCAP mRNA

NCBI chr 8:110,306,026...110,360,677
Ensembl chr 8:110,306,031...110,360,666

G

scavenger receptor class F, member 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SCARF1 mRNA

NCBI chr10:60,359,213...60,371,516
Ensembl chr10:60,359,197...60,371,516

G

Scm polycomb group protein like 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in decreased expression of SCML1 mRNA

NCBI chr X:32,893,100...32,912,686
Ensembl chr X:32,894,327...32,911,366

G

sodium channel epithelial 1 subunit beta

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SCNN1B mRNA

NCBI chr 1:176,430,063...176,484,451
Ensembl chr 1:176,430,103...176,484,451

G

secernin 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SCRN2 mRNA

NCBI chr10:82,016,604...82,020,676
Ensembl chr10:82,016,649...82,020,675

G

stromal cell-derived factor 2-like 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SDF2L1 mRNA

NCBI chr11:83,872,659...83,874,902
Ensembl chr11:83,872,659...83,874,902

G

succinate dehydrogenase complex assembly factor 3

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SDHAF3 mRNA

NCBI chr 4:35,100,533...35,160,740
Ensembl chr 4:35,100,506...35,160,749

G

SEC11 homolog C, signal peptidase complex subunit

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SEC11C mRNA

NCBI chr18:59,320,932...59,337,272
Ensembl chr18:59,320,884...59,337,364

G

SEC31 homolog A, COPII coat complex component

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SEC31A mRNA

NCBI chr14:9,214,324...9,269,281
Ensembl chr14:9,214,349...9,269,273

G

selenoprotein W

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SELENOW mRNA

NCBI chr 1:76,599,441...76,604,514
Ensembl chr 1:76,598,779...76,604,724
Ensembl chr 1:76,598,779...76,604,724

G

selectin P ligand

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in decreased expression of SELPLG mRNA

NCBI chr12:42,796,690...42,809,908
Ensembl chr12:42,796,580...42,812,585

G

semaphorin 4A

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SEMA4A mRNA

NCBI chr 2:173,896,432...173,917,903
Ensembl chr 2:173,896,439...173,914,442

G

septin 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SEPTIN2 mRNA

NCBI chr 9:94,018,141...94,051,386
Ensembl chr 9:94,018,208...94,051,386

G

stress-associated endoplasmic reticulum protein family member 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SERP2 mRNA

NCBI chr15:51,879,882...51,903,958
Ensembl chr15:51,879,877...51,904,785

G

serpin family E member 1

multiple interactions
decreases expression

[troglitazone co-treated with [Hydrochlorothiazide co-treated with Hydralazine co-treated with Reserpine]] results in decreased expression of SERPINE1 mRNA; [troglitazone co-treated with [Hydrochlorothiazide co-treated with Hydralazine co-treated with Reserpine]] results in decreased expression of SERPINE1 protein
Hydralazine results in decreased expression of SERPINE1 mRNA

PMID:11318962 PMID:23415681

NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657

G

serpin family G member 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SERPING1 mRNA

NCBI chr 3:69,842,726...69,852,583
Ensembl chr 3:69,842,739...69,852,034

G

SERTA domain containing 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SERTAD2 mRNA

NCBI chr14:94,733,637...94,838,200
Ensembl chr14:94,733,579...94,838,313

G

splicing factor 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SF1 mRNA

NCBI chr 1:203,670,016...203,683,432
Ensembl chr 1:203,670,018...203,684,330

G

splicing factor 3B, subunit 6

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SF3B6 mRNA

NCBI chr 6:27,826,044...27,835,086
Ensembl chr 6:27,826,029...27,835,156

G

SH3 and multiple ankyrin repeat domains 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SHANK2 mRNA

NCBI chr 1:199,146,210...199,590,962
Ensembl chr 1:199,169,429...199,589,394

G

shisa family member 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SHISA2 mRNA

NCBI chr15:33,806,715...33,811,013
Ensembl chr15:33,805,958...33,811,013

G

shortage in chiasmata 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SHOC1 mRNA

NCBI chr 5:73,864,423...73,956,487
Ensembl chr 5:73,866,334...73,956,444

G

SHOX homeobox 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in decreased expression of SHOX2 mRNA

NCBI chr 2:151,217,049...151,227,180
Ensembl chr 2:151,217,552...151,227,143

G

SID1 transmembrane family, member 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SIDT2 mRNA

NCBI chr 8:46,232,379...46,248,913
Ensembl chr 8:46,232,383...46,248,700

G

signal-induced proliferation-associated 1 like 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SIPA1L1 mRNA

NCBI chr 6:101,839,351...102,118,408
Ensembl chr 6:101,839,404...102,116,950

G

Ski proto-oncogene

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in decreased expression of SKI mRNA

NCBI chr 5:165,713,525...165,782,134
Ensembl chr 5:165,714,093...165,782,733

G

solute carrier family 12 member 3

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC12A3 mRNA

NCBI chr19:10,630,651...10,679,250
Ensembl chr19:10,631,393...10,669,091

G

solute carrier family 16 member 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC16A2 mRNA

NCBI chr X:68,725,365...68,848,572
Ensembl chr X:68,723,261...68,848,771

G

solute carrier family 17 member 9

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC17A9 mRNA

NCBI chr 3:167,839,246...167,857,462
Ensembl chr 3:167,839,385...167,855,985

G

solute carrier family 19 member 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC19A2 mRNA

NCBI chr13:76,601,975...76,616,175
Ensembl chr13:76,601,900...76,616,172

G

solute carrier family 22 member 16

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC22A16 mRNA

NCBI chr20:43,972,808...44,068,447
Ensembl chr20:43,972,836...44,065,019

G

solute carrier family 22, member 17

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC22A17 mRNA

NCBI chr15:28,382,285...28,389,435
Ensembl chr15:28,382,292...28,388,799

G

solute carrier family 22 member 2

multiple interactions

Hydralazine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268

G

solute carrier family 23, member 3

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC23A3 mRNA

NCBI chr 9:76,622,621...76,633,188
Ensembl chr 9:76,622,800...76,631,366

G

solute carrier family 25 member 13

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC25A13 mRNA

NCBI chr 4:34,179,224...34,361,912
Ensembl chr 4:34,179,224...34,361,902

G

solute carrier family 25 member 5

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC25A5 mRNA

NCBI chr X:116,031,896...116,034,963
Ensembl chr X:116,031,803...116,034,967

G

solute carrier family 2 member 9

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC2A9 mRNA

NCBI chr14:72,328,334...72,461,981
Ensembl chr14:72,328,320...72,461,981

G

solute carrier family 30 member 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC30A2 mRNA

NCBI chr 5:146,559,733...146,571,957
Ensembl chr 5:146,559,733...146,571,956

G

solute carrier family 35 member C1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC35C1 mRNA

NCBI chr 3:78,421,925...78,429,603
Ensembl chr 3:78,421,933...78,428,520

G

solute carrier family 3 member 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC3A2 mRNA

NCBI chr 1:205,604,468...205,618,931
Ensembl chr 1:205,604,468...205,618,931

G

solute carrier family 6 member 13

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC6A13 mRNA

NCBI chr 4:154,539,246...154,577,784
Ensembl chr 4:154,540,468...154,576,152

G

solute carrier family 6 member 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC6A2 mRNA

NCBI chr19:14,010,292...14,055,317
Ensembl chr19:14,010,386...14,050,357

G

solute carrier family 8 member B1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SLC8B1 mRNA

NCBI chr12:36,029,759...36,053,087
Ensembl chr12:36,029,760...36,053,031

G

SRA stem-loop interacting RNA binding protein

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SLIRP mRNA

NCBI chr 6:107,088,760...107,097,791
Ensembl chr 6:107,088,403...107,097,791

G

SWI/SNF related BAF chromatin remodeling complex subunit C1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SMARCC1 mRNA

NCBI chr 8:110,111,097...110,214,734
Ensembl chr 8:110,111,122...110,214,720

G

smoothened, frizzled class receptor

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SMO mRNA

NCBI chr 4:58,343,626...58,373,823
Ensembl chr 4:58,343,529...58,373,829

G

SMAD specific E3 ubiquitin protein ligase 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SMURF2 mRNA

NCBI chr10:91,761,798...91,862,485
Ensembl chr10:91,761,807...91,862,488

G

snail family transcriptional repressor 3

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SNAI3 mRNA

NCBI chr19:50,516,771...50,529,295
Ensembl chr19:50,516,771...50,523,486

G

SNF8 subunit of ESCRT-II

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SNF8 mRNA

NCBI chr10:80,984,337...80,996,724
Ensembl chr10:80,984,363...80,996,734

G

small nuclear ribonucleoprotein U1 subunit 70

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SNRNP70 mRNA

NCBI chr 1:95,856,038...95,876,434
Ensembl chr 1:95,856,036...95,876,392

G

small nuclear ribonucleoprotein polypeptides B and B1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SNRPB mRNA

NCBI chr 3:117,369,816...117,379,344
Ensembl chr 3:117,370,100...117,379,339

G

small nuclear ribonucleoprotein polypeptide B2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SNRPB2 mRNA

NCBI chr 3:130,399,239...130,408,821
Ensembl chr 3:130,399,248...130,408,812

G

small nuclear ribonucleoprotein D2 polypeptide

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SNRPD2 mRNA

NCBI chr 1:78,798,377...78,801,227
Ensembl chr 1:78,798,377...78,803,351
Ensembl chr20:78,798,377...78,803,351

G

small nuclear ribonucleoprotein polypeptide G

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SNRPG mRNA

NCBI chr 4:118,812,278...118,819,827
Ensembl chr 4:118,812,252...118,819,826
Ensembl chr X:118,812,252...118,819,826

G

small nuclear ribonucleoprotein 13

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SNU13 mRNA

NCBI chr 7:113,565,293...113,570,887
Ensembl chr 7:113,565,295...113,570,872
Ensembl chr 1:113,565,295...113,570,872

G

SRY-box transcription factor 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SOX1 mRNA

NCBI chr16:77,135,577...77,139,592
Ensembl chr16:77,137,584...77,138,762

G

SRY-box transcription factor 9

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SOX9 mRNA

NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994

G

SAM pointed domain containing ets transcription factor

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SPDEF mRNA

NCBI chr20:5,771,440...5,785,893
Ensembl chr20:5,771,441...5,785,893

G

serine peptidase inhibitor, Kunitz type 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SPINT1 mRNA

NCBI chr 3:106,231,082...106,244,121
Ensembl chr 3:106,231,444...106,244,119

G

small proline-rich protein 1A

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in decreased expression of SPRR1A mRNA

NCBI chr 2:178,055,096...178,057,012
Ensembl chr 2:178,055,096...178,057,063

G

small proline-rich protein 1B

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in decreased expression of SPRR1B mRNA

NCBI chr 2:178,008,844...178,010,742
Ensembl chr 2:178,009,130...178,009,567

G

splA/ryanodine receptor domain and SOCS box containing 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SPSB2 mRNA

NCBI chr 4:157,613,404...157,615,293
Ensembl chr 4:157,613,401...157,615,284

G

signal recognition particle 72

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SRP72 mRNA

NCBI chr14:31,168,175...31,195,717
Ensembl chr14:31,168,293...31,195,729

G

signal recognition particle 9

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SRP9 mRNA

NCBI chr13:93,832,580...93,840,720
Ensembl chr13:93,832,580...93,840,720

G

SRSF protein kinase 3

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SRPK3 mRNA

NCBI chr X:151,510,452...151,515,208
Ensembl chr X:151,510,539...151,515,198

G

sulfiredoxin 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SRXN1 mRNA

NCBI chr 3:140,604,490...140,610,050
Ensembl chr 3:140,599,608...140,628,448

G

single stranded DNA binding protein 4

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SSBP4 mRNA

NCBI chr16:18,828,014...18,838,941
Ensembl chr16:18,828,054...18,838,947

G

sarcospan

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SSPN mRNA

NCBI chr 4:178,890,030...178,946,267
Ensembl chr 4:178,897,147...178,931,554

G

signal sequence receptor subunit 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SSR1 mRNA

NCBI chr17:26,833,720...26,861,821
Ensembl chr17:26,833,741...26,861,821

G

ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of ST8SIA2 mRNA

NCBI chr 1:127,762,573...127,838,017
Ensembl chr 1:127,762,573...127,838,091

G

stabilin 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of STAB2 mRNA

NCBI chr 7:21,249,426...21,433,051
Ensembl chr 7:21,249,391...21,434,042

G

STAG1 cohesin complex component

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of STAG1 mRNA

NCBI chr 8:101,179,039...101,564,684
Ensembl chr 8:101,179,039...101,564,677

G

STEAP2 metalloreductase

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in decreased expression of STEAP2 mRNA

NCBI chr 4:28,347,769...28,368,177
Ensembl chr 4:28,348,362...28,375,791

G

serine/threonine kinase 38

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of STK38 mRNA

NCBI chr20:7,034,245...7,067,803
Ensembl chr20:7,034,242...7,068,198

G

syntaxin 11

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of STX11 mRNA

NCBI chr 1:7,293,427...7,320,060
Ensembl chr 1:7,289,976...7,320,164

G

syntaxin 5

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of STX5 mRNA

NCBI chr 1:205,637,401...205,653,563
Ensembl chr 1:205,637,413...205,653,563

G

serine/threonine/tyrosine interacting protein

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of STYX mRNA

NCBI chr15:18,565,214...18,595,797
Ensembl chr15:18,564,633...18,593,524

G

SUFU negative regulator of hedgehog signaling

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SUFU mRNA

NCBI chr 1:245,257,725...245,355,576
Ensembl chr 1:245,257,768...245,355,577

G

small ubiquitin-like modifier 3

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SUMO3 mRNA

NCBI chr20:11,010,140...11,020,850
Ensembl chr20:11,007,148...11,020,877
Ensembl chr20:11,007,148...11,020,877

G

synaptophysin

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SYP mRNA

NCBI chr X:14,849,444...14,864,553
Ensembl chr X:14,849,444...14,864,745

G

synaptotagmin 6

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of SYT6 mRNA

NCBI chr 2:191,093,009...191,152,283
Ensembl chr 2:191,093,007...191,149,956

G

transforming, acidic coiled-coil containing protein 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of TACC2 mRNA

NCBI chr 1:185,139,223...185,327,881
Ensembl chr 1:185,116,111...185,327,881

G

TATA-box binding protein associated factor 12

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of TAF12 mRNA

NCBI chr 5:144,472,816...144,490,299
Ensembl chr 5:144,472,841...144,488,849

G

TAFA chemokine like family member 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of TAFA1 mRNA

NCBI chr 4:128,738,028...129,244,223
Ensembl chr 4:128,739,313...129,243,777

G

transaldolase 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of TALDO1 mRNA

NCBI chr 1:196,493,634...196,503,965
Ensembl chr 1:196,493,589...196,503,974

G

TBC1 domain family member 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of TBC1D1 mRNA

NCBI chr14:43,936,820...44,135,133
Ensembl chr14:43,935,636...44,136,499

G

tubulin folding cofactor D

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of TBCD mRNA

NCBI chr10:106,717,340...106,874,126
Ensembl chr10:106,717,367...106,874,122

G

transforming growth factor beta regulator 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of TBRG1 mRNA

NCBI chr 8:37,355,274...37,362,933
Ensembl chr 8:37,354,658...37,362,930

G

T-box transcription factor 18

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of TBX18 mRNA

NCBI chr 8:88,652,054...88,680,081
Ensembl chr 8:88,652,054...88,680,058

G

transcription elongation regulator 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of TCERG1 mRNA

NCBI chr18:34,505,708...34,566,470
Ensembl chr18:34,505,751...34,566,470

G

transcription factor 12

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of TCF12 mRNA

NCBI chr 8:72,490,447...72,799,265
Ensembl chr 8:72,492,567...72,799,201

G

tec protein tyrosine kinase

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of TEC mRNA

NCBI chr14:35,352,551...35,461,585
Ensembl chr14:35,352,829...35,461,557

G

terminal nucleotidyltransferase 5A

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of TENT5A mRNA

NCBI chr 8:86,222,294...86,229,045
Ensembl chr 8:86,225,357...86,229,045

G

transcription factor CP2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of TFCP2 mRNA

NCBI chr 7:131,616,777...131,658,995
Ensembl chr 7:131,616,785...131,658,939

G

transcription factor Dp-1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of TFDP1 mRNA

NCBI chr16:76,162,040...76,200,871
Ensembl chr16:76,162,043...76,200,817

G

trefoil factor 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of TFF2 mRNA

NCBI chr20:9,215,750...9,219,619
Ensembl chr20:9,215,761...9,219,619

G

TGFB-induced factor homeobox 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of TGIF2 mRNA

NCBI chr 3:145,333,152...145,348,599
Ensembl chr 3:145,333,418...145,348,596
Ensembl chr17:145,333,418...145,348,596

G

thrombomodulin

multiple interactions

Hydralazine inhibits the reaction [Nitric Oxide deficiency results in decreased expression of THBD protein]

NCBI chr 3:135,863,366...135,867,018
Ensembl chr 3:135,862,835...135,867,193

G

thioesterase superfamily member 6

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of THEM6 mRNA

NCBI chr 7:106,606,570...106,609,747
Ensembl chr 7:106,606,570...106,609,746

G

thyroid hormone receptor associated protein 3

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of THRAP3 mRNA

NCBI chr 5:138,445,284...138,487,544
Ensembl chr 5:138,445,295...138,487,477

G

Thy-1 cell surface antigen

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of THY1 mRNA

NCBI chr 8:44,389,495...44,394,688
Ensembl chr 8:44,389,513...44,394,659

G

translocase of inner mitochondrial membrane 13

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of TIMM13 mRNA

NCBI chr 7:8,809,069...8,810,172
Ensembl chr 7:8,809,058...8,809,910

G

translocase of inner mitochondrial membrane 50

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of TIMM50 mRNA

NCBI chr 1:83,574,872...83,582,748
Ensembl chr 1:83,556,757...83,582,793

G

translocase of inner mitochondrial membrane 8 homolog B

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of TIMM8B mRNA

NCBI chr 8:50,954,350...50,955,730
Ensembl chr 8:50,954,342...50,955,729

G

TIMP metallopeptidase inhibitor 1

decreases expression

hydralazine decreases expression of Timp1 protein in blood serum

RGD

NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664

G

TIMP metallopeptidase inhibitor 2

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of TIMP2 mRNA

NCBI chr10:103,541,199...103,590,611
Ensembl chr10:103,531,505...103,590,611

G

TOR signaling pathway regulator

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of TIPRL mRNA

NCBI chr13:77,527,176...77,552,026
Ensembl chr13:77,527,176...77,552,074

G

TLE family member 5, transcriptional modulator

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of TLE5 mRNA

NCBI chr 7:8,143,357...8,150,295
Ensembl chr 7:8,143,357...8,150,113

G

transmembrane 7 superfamily member 3

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of TM7SF3 mRNA

NCBI chr 4:179,518,127...179,550,154
Ensembl chr 4:179,518,130...179,550,154

G

translation machinery associated 7 homolog

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of TMA7 mRNA

NCBI chr 8:109,726,213...109,730,902
Ensembl chr 8:109,726,196...109,735,474

G

transmembrane and coiled-coil domains 1

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of TMCO1 mRNA

NCBI chr13:79,460,229...79,483,557
Ensembl chr13:79,460,135...79,483,555

G

transmembrane p24 trafficking protein 3

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of TMED3 mRNA

NCBI chr 8:90,241,516...90,249,429
Ensembl chr 8:90,241,516...90,249,346

G

transmembrane protein 248

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of TMEM248 mRNA

NCBI chr12:26,430,775...26,457,105
Ensembl chr12:26,432,953...26,457,105

G

transmembrane protein 260

multiple interactions

[Hydralazine co-treated with Valproic Acid] results in increased expression of TMEM260 mRNA

NCBI chr15:21,734,119...21,804,049
Ensembl chr15:21,734,151...21,806,801